Novel lipids for delivering nucleic acid therapeutic agents

By combining novel cationic lipids with other lipids and polymers to form lipid nanoparticle compositions, the problems of insufficient protection, high degradation risk, and high toxicity of existing lipid nanoparticles in nucleic acid delivery are solved, achieving highly efficient nucleic acid delivery.

CN123124979APending Publication Date: 2026-11-17POPVAX PTE LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202580024248.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-08
Filing Date
2025-04-08
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing lipid nanoparticles as nucleic acid delivery carriers suffer from insufficient protection, high risk of degradation, high toxicity, low encapsulation efficiency, and endosome escape problems, making it difficult to efficiently deliver nucleic acid therapeutic agents.

Method used

Develop novel cationic lipids and their isomers and salts, and combine them with other lipids and polymers to form lipid nanoparticle compositions for the delivery of nucleic acid therapeutic agents.

Benefits of technology

This improved the protective efficiency of nucleic acid therapeutic agents, reduced toxicity, enhanced endosomal escape ability, improved encapsulation efficiency and biodegradability, and achieved efficient nucleic acid delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124979A_ABST
    Figure CN123124979A_ABST
Patent Text Reader

Abstract

This disclosure generally relates to novel lipids and lipid nanoparticles or compositions thereof for delivering nucleic acid therapeutic agents. Furthermore, this disclosure generally relates to methods for treating or preventing disease, said methods comprising administering the novel lipid and lipid nanoparticle compositions described herein to a subject in need.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference with related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 575942, filed April 8, 2024, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention provides lipid and lipid nanoparticle (LNP) compositions or formulations for use in nucleic acid therapeutic agents. Background Technology

[0004] Small molecule and protein-based drugs or therapeutics have been used for decades. In recent years, nucleic acid-based therapies have emerged as a promising class of drugs. These drugs contain segments of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). Delivering nucleic acids to target cells has been a challenge due to the lack of suitable nucleic acid delivery vectors. Viral vectors have been used for this purpose, but the innate immune response to these vectors and their transgenic products poses a significant obstacle to their wider application.

[0005] In recent years, lipid nanoparticles (LNPs) have attracted widespread attention as delivery carriers for nucleic acid therapeutics. Patisiran is the first FDA-approved short interfering RNA (siRNA) therapeutic encapsulated in lipid nanoparticles. Lipid nanoparticles typically contain four different types of lipids: cationic / ionizable lipids, phospholipids, sterols, and PEG-lipids. Cationic or ionizable lipids play a crucial role in delivering nucleic acid therapeutics into cells. Efforts are underway to develop novel cationic lipids or improve existing cationic lipids for delivering nucleic acid therapeutics, providing protection against degradation, reducing toxicity, improving encapsulation efficiency, maximizing endosome escape, and enhancing biodegradability. Designing highly efficient cationic lipids for delivering nucleic acid therapeutics remains a challenging area.

[0006] Therefore, there is a need for novel cationic lipid and lipid nanoparticle compositions for delivering nucleic acid-based therapeutic agents. Summary of the Invention

[0007] Therefore, novel cationic lipids, including their isomers and salts, are provided for the delivery of nucleic acid therapeutic agents. They can be used alone or in combination with other lipid and polymer components for the delivery of nucleic acid therapeutic agents.

[0008] In one embodiment, this disclosure relates to a cationic lipid represented by formula (I) or an isomer or salt thereof:

[0009] Formula (I), in: R1 and R2 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L7-R5 and -NR6R7; R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L6, and L7 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N, provided that when A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or S, one of R1 or R2 does not exist; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0010] In some embodiments, this disclosure relates to a cationic lipid represented by formula (II) or an isomer or salt thereof:

[0011] Equation (II), in: R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; (R 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L7, and L8 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Z is -CH2-, O, N, or S; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0012] In some embodiments, this disclosure relates to a lipid nanoparticle composition comprising any cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids described herein.

[0013] In some embodiments, this disclosure relates to a lipid nanoparticle composition comprising any cationic lipid, ionizable polymer, phospholipid, sterol, PEG-lipid, and nucleic acid described herein.

[0014] In some embodiments, the nucleic acid is DNA, RNA, or a combination thereof. The RNA may be messenger RNA (mRNA), non-coding RNA (ncRNA), or a combination thereof. The non-coding RNA (ncRNA) may be long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), transfer RNA (tRNA), or ribosomal RNA (rRNA), or a combination thereof.

[0015] In some embodiments, the nucleic acid encodes an antigen. The antigen may be derived from an infectious pathogen, such as a virus or bacteria.

[0016] In some implementations, the nucleic acid regulates or modulates cell function.

[0017] In some embodiments, the nucleic acid contains at least one chemical modification.

[0018] In some respects, this article provides a nucleic acid vaccine or therapeutic agent comprising the lipid nanoparticle composition described herein.

[0019] In some respects, this article provides a method for treating or preventing disease, the method comprising administering a lipid nanoparticle composition to a subject in need, the composition comprising the cationic lipids, phospholipids, sterols, PEG-lipids and nucleic acids described herein.

[0020] In some respects, this disclosure relates to the use of lipid nanoparticle compositions comprising the cationic lipids, phospholipids, sterols, PEG-lipids and nucleic acids described herein in the preparation of medicaments for the treatment or prevention of disease in subjects.

[0021] In some embodiments, the disease is cancer, an infectious disease, or a disease and / or disorder that is improved by humoral and / or cellular immune responses. Attached Figure Description

[0022] Figure 1 – The expression of luciferase mRNA in different lipid nanoparticle compositions or formulations was depicted. Detailed Implementation

[0023] Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Some of these terms are briefly defined below; such definitions should not be construed as restrictive.

[0024] Unless the context otherwise requires, references without a specific number as used herein include plural references. Similarly, unless the context otherwise requires, any singular term used herein means plural, and vice versa. As used herein in the claims, references without a specific number, when used in conjunction with the word “comprising,” may mean one or more. The term “another” as used herein may mean at least a second or more.

[0025] It must be pointed out that the words “contains” or any form thereof, “has” or any form thereof, “includes” or any form thereof, or “contains” or any form thereof are open-ended and do not exclude other undescribed elements or methodological steps.

[0026] As long as any quantity or range is stated, those skilled in the art will recognize that quantities or ranges within 10% or 20% of the stated values ​​may also be considered appropriate and reasonable and included within the scope of the invention.

[0027] Unless otherwise defined herein, the scientific and technical terms used in connection with this invention shall have the meanings commonly understood by those skilled in the art. Generally, the terms and techniques described herein and used in connection with cell and tissue culture, molecular biology, immunology, microbiology, proteins, adjuvants, pharmaceutical biotechnology, and biopharmaceutical manufacturing are well-known and commonly used in the art. The methods and techniques of this invention are generally performed according to conventional methods known in the art and described in various general and more specific references cited and discussed throughout this specification. The cationic lipids of this disclosure can be synthesized using the methods described herein as well as alternative synthetic methods well-known to those skilled in the art. Starting materials can be sourced from various suppliers or produced using conventional methods known in the art. Various organic synthetic methods are disclosed in standard textbooks, such as Smith, Michael B., *Compendium of Organic Synthetic Methods*, Vol. 13, 2014, John Wiley & Sons, Inc. During synthesis, it may be necessary and / or desirable to protect sensitive or reactive groups on any molecules of interest. This can be achieved using standard techniques known to those skilled in the art, such as Wuts, Peter GM, *Greene's Protective Groups in Organic Synthesis*, 5th Edition, 2014, John Wiley & Sons, Inc. The exemplary cationic lipids described herein can be prepared according to the reaction protocols described herein. These methods can be adapted or modified in ways known to those skilled in the art.

[0028] As used in this article, the term "isomer" refers to another compound having the same molecular formula but different atomic arrangements or configurations, including isomers, stereoisomers, diastereomers, or enantiomers.

[0029] As used herein, the term "salt" means a salt prepared from a pharmaceutically acceptable, non-toxic base or acid (including inorganic bases or acids and organic bases or acids). Where the compounds of this invention contain one or more acidic or basic groups, this invention also includes their corresponding pharmaceutically or toxicologically acceptable salts, particularly pharmaceutically usable salts.

[0030] The symbol used in this article is " " indicates a single or double bond.

[0031] As used herein, the term "alkyl" refers to a straight (unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing a saturated carbon chain.

[0032] As used herein, the term "alkenyl" refers to a straight (unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing at least one carbon-carbon double bond.

[0033] As used in this article, the term "alkynyl" refers to a straight (unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing at least one carbon-carbon triple bond.

[0034] As used in this article, the term "alkylene" refers to a divalent straight-chain (unbranched) or branched, substituted or unsubstituted saturated hydrocarbon chain.

[0035] As used herein, the term "alkenyl" refers to a divalent straight-chain (unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing at least one carbon-carbon double bond.

[0036] As used herein, the term "ethynyl group" refers to a divalent straight-chain (unbranched) or branched, substituted or unsubstituted hydrocarbon chain containing at least one carbon-carbon triple bond.

[0037] As used in this article, the term "hydrocarbon chain" refers to the simplest chain consisting only of carbon and hydrogen atoms, which can be straight (unbranched) or branched, substituted or unsubstituted, and saturated or unsaturated.

[0038] The terms “ring” or “loop” are used interchangeably herein, whether as a prefix, infix, or suffix, referring to a structure characterized by one or more loops. In some embodiments, two or more loops may be connected to form double-ring, triple-ring, quadruple-ring, pentagonal, or multi-ring structures. These ring structures may exhibit different configurations, such as fused, bridged, spiral, inverse, etc.

[0039] As used herein, the term "cycloalkyl" refers to a non-aromatic carbonyl cyclic compound consisting of at least three carbon atoms, either saturated or unsaturated, optionally substituted.

[0040] As used herein, the term "heterocyclic alkyl" means a cycloalkyl group in which at least one carbon atom of the cycloalkyl ring is replaced by a heteroatom (e.g., but not limited to nitrogen, oxygen, sulfur, or phosphorus). In some embodiments, the heterocyclic alkyl group may be substituted with one or more substituents. In some embodiments, the substitution may be on one or more carbon atoms of the heterocyclic alkyl group or on one or more heteroatoms of the heterocyclic alkyl group.

[0041] As used in this article, the term "aryl" refers to a monovalent organic group derived from an aromatic hydrocarbon by removing a hydrogen atom.

[0042] As used herein, the term "heteroaryl" refers to a group or part of a group containing an aromatic carbonyl cyclic portion of 5 to 10 ring atoms, wherein one or more (in some embodiments, one, two, or three) of the ring atoms are selected from nitrogen, oxygen, phosphorus, or sulfur, and the remaining ring atoms are carbon. In some embodiments, the heteroaryl group may be substituted with one or more substituents. In some embodiments, the substitution may be on one or more carbon atoms of the heteroaryl group or on one or more heteroatoms of the heteroaryl group.

[0043] As used in this article, the term "divalent" refers to a chemical moiety having two unoccupied valences (to form bonds with another chemical moiety).

[0044] As used in this article, the term "unit valence" refers to a chemical moiety having a single unoccupied valence (to form a bond with another chemical moiety).

[0045] The terms “substituent,” “substituted,” or “substituted” are used interchangeably to refer to all permissible substitutions in an organic compound. These modifications involve an atom or group that substitutes for another atom or group, or an atom or group thereon with a substituted atom or group. Furthermore, the terms “substituted” or “substituted” include the implicit condition that such substitution meets the permissible valence of the substituted atom or group and the substituent. In some embodiments, the substituent may include further substitutions. In some embodiments, the substituent may be selected from, but is not limited to, H, -OH, Cl, Br, I, O, S, N, P, C. 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkylene, C 1-6 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Heteroaryl groups can be further substituted. In some embodiments, the substituents can be further replaced by H, -OH, Cl, Br, I, or C. 1-6 Hydroxyalkyl substitution.

[0046] The terms “composition,” “formulation,” “lipid nanoparticle composition,” “LNP composition,” “LNP formulation,” “LNP,” or “lipid nanoparticle” are used interchangeably to refer to nanoparticles, nanostructures, vesicles, liposomes, compositions, or formulations comprising one or more lipid components (e.g., cationic lipids, phospholipids, sterols, and PEG-lipids) and / or ionizable polymer components. In some embodiments, the lipid nanoparticles comprise cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids. In some embodiments, the lipid nanoparticles comprise one or more lipid components, ionizable polymer components, and nucleic acids. In some embodiments, the nucleic acid bound to the lipid nanoparticles is DNA, mRNA, microRNA, small interfering RNA, small nucleolar RNA, small nuclear RNA, long noncoding RNA, or combinations thereof. In some embodiments, the lipid nanoparticle composition may contain one or more drug carriers or excipients, such as, but not limited to, buffers, stabilizers, tension modifiers, surfactants, chelating agents, salts, antioxidants, diluents, and / or preservatives, or combinations thereof. The term lipid nanoparticles also refers to lipid nanoparticles that do not contain any encapsulated nucleic acids (empty lipid nanoparticles or empty-shell lipid nanoparticles). In some embodiments, the lipid nanoparticle composition comprises lipid nanoparticles having encapsulated nucleic acids as well as empty lipid nanoparticles.

[0047] The terms “therapeutic agent,” “therapeutic agent,” “preventive agent,” “preventive agent,” or “drug” are used interchangeably to refer to a compound or composition (such as the lipid nanoparticle composition described herein) that has a biological effect or combination of biological effects, which prevents, inhibits, eliminates, or prevents the progression of disease or other abnormal biological processes in a subject (e.g., an animal or a human).

[0048] The term "prevention" is recognized in the art and is well understood in the art when used in association with a condition such as an infection, and includes administering a composition that reduces the frequency or severity of one or more symptoms of a medical condition in a subject compared to a subject who has not received the composition. Therefore, prevention of a condition (e.g., an infection) includes, for example, reducing the frequency or severity of one or more symptoms of the medical condition in a patient population receiving the treatment, in a statistically and / or clinically significant amount, relative to a control group that has not received the treatment. Similarly, prevention of an infection includes reducing the likelihood of a patient receiving the treatment developing the infection or related symptoms compared to a patient who has not received the treatment.

[0049] As used herein, the term "stable" means a composition that retains an acceptable level of physical stability, chemical stability, and / or biological activity after being stored at a given temperature for a specified period of time. The stability of a therapeutic agent can be measured using techniques known to those skilled in the art, such as by SDS-PAGE, dynamic light scattering, or immunogenicity assays. A composition may be considered stable even if the nucleic acids contained within it do not retain 100% of their structure and / or function and / or biological activity after the specified storage time. In some cases, maintaining at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the nucleic acid structure and / or function and / or biological activity after the specified storage time can be considered "stable." In some implementations, nucleic acid structures and / or functions and / or biological activities that are maintained at about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, or about 70% to about 80% after a specified storage period can be considered "stable".

[0050] As used in this article, "specified time period" means at least approximately 1 week, at least approximately 2 weeks, at least approximately 3 weeks, at least approximately 4 weeks, at least approximately 5 weeks, at least approximately 6 weeks, at least approximately 7 weeks, at least approximately 8 weeks, at least approximately 9 weeks, at least approximately 10 weeks, at least approximately 12 weeks, at least approximately 14 weeks, at least approximately 16 weeks, at least approximately 18 weeks, at least approximately 20 weeks, at least approximately 22 weeks, at least approximately 24 weeks, at least approximately 28 weeks, at least approximately 32 weeks, at least approximately 36 weeks, at least approximately 40 weeks, at least approximately 44 weeks, at least approximately 48 weeks, at least approximately 52 weeks, or longer. In some implementations, the specified time period also means at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 14 months, at least about 16 months, at least about 18 months, at least about 20 months, at least about 22 months, at least about 24 months, or longer. In some implementations, the specified time period also means at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, or longer.

[0051] The terms “mol%”, “mol%”, “mol%”, or “mol%” are used interchangeably to refer to the number of moles of a component, expressed as a percentage of the total number of moles of all lipid components present in the lipid nanoparticle composition described herein. For example, 50 mol% cationic lipids means that 50 mol% of cationic lipids are present in the lipid nanoparticle composition, with other lipid components collectively constituting the remaining 50 mol%, such that the total amount of all lipid components constitutes 100 mol%. In some embodiments, mol% also refers to the number of moles of a component, expressed as a percentage of the total number of moles of all lipid components (such as cationic lipids, phospholipids, sterols, and PEG-lipids) and ionizable polymer components present in the lipid nanoparticle composition described herein. For example, 50 mol% cationic lipids means that 50 mol% of cationic lipids are present in the lipid nanoparticle composition, with other lipid components and ionizable polymer components collectively constituting the remaining 50 mol%, such that the total amount of all lipid components and ionizable polymer components constitutes 100 mol.

[0052] The terms “N / P ratio,” “N:P ratio,” “N / P,” “N:P,” “lipid to nucleic acid ratio,” or “cationic lipid to nucleic acid ratio” are used interchangeably herein and refer to the ratio (molar ratio) of the positive charge in the cationic lipid to the negative charge in the nucleic acid in a lipid nanoparticle. In some embodiments, the N / P ratio refers to the ratio of protonable nitrogen present in the cationic lipid to the phosphate group present in the nucleic acid in the lipid nanoparticle. In some embodiments, the N / P ratio is between 1 and 18 (i.e., 1:1 to 18:1). For example, an N / P ratio of 18 means that there are 18 protonable nitrogen groups of cationic lipid in the lipid nanoparticle relative to 1 phosphate group of nucleic acid.

[0053] The terms “protein” or “peptide” and “polypeptide” are used interchangeably herein to refer to a polymer of amino acids linked by peptide bonds, but do not imply any particular length. The terms also include fusion proteins, mutant proteins, analogs, or modified forms.

[0054] The term "antibody" refers to any antibody or antibody fragment (whether naturally occurring or recombinant) that retains antigen-binding activity. This includes monoclonal or polyclonal antibodies, single-chain antibodies, Fab fragments of monoclonal or polyclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, bispecific antibodies, multispecific antibodies, or nanobodies.

[0055] As used in this article, the term "buffer" refers to those reagents that maintain the pH of a solution within the desired range.

[0056] The term “cell” as used in this article refers to a single cell, a group of cells, or multiple cells.

[0057] As used herein, the terms "bioeffective amount" or "therapeutic effective amount" refer to the amount of a pharmaceutical agent (e.g., a therapeutic agent, drug, therapeutic agent, preventive agent, diagnostic agent, composition, etc.) that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat, prevent, diagnose, improve symptoms, and / or delay the onset of said infection, disease, disorder, and / or condition. Therapeutic effective amounts as used herein may vary depending on factors such as the patient's disease state, age, sex, and weight.

[0058] As used herein, the term "treatment" includes alleviating, preventing, or reversing symptoms, clinical signs, or underlying pathology of a condition to stabilize or improve the subject's condition or reduce the likelihood that the subject's condition would worsen as if the subject had not received treatment. Treatment may be administered to subjects who do not exhibit signs of disease and / or only exhibit early signs of disease, with the aim of reducing the risk of developing pathological changes associated with the disease.

[0059] As used herein, the term "subject" refers to a living mammal and may be used interchangeably with the term "patient." Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other ape and monkey species; farm animals such as cattle, horses, sheep, goats, and pigs; livestock such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. The terms do not indicate a specific age or sex.

[0060] Individuals described herein as being “at risk” for a particular disease, disorder, or condition may or may not have a detectable disease or symptoms, and may or may not have exhibited a detectable disease or symptoms prior to the treatments described herein. “At risk” means that an individual possesses one or more risk factors, which are measurable parameters known in the art associated with the occurrence of a particular disease, disorder, or condition. Individuals possessing one or more of these risk factors are more likely to develop a particular disease, disorder, or condition than individuals without one or more of these risk factors.

[0061] As used in this article, the term "disease" means an interruption, cessation, or impairment of bodily function, system, or organ. Non-limiting examples of disease include malignant diseases, autoimmune diseases, genetic diseases, metabolic disorders, rare diseases, cardiovascular diseases, neurological diseases, disorders of gene or protein regulation, or infectious diseases.

[0062] As used herein, “combined” administration with another compound or composition includes simultaneous administration and / or administration at different times. Combined administration also covers administration as a co-preparation or as separate compositions, including administration at different frequencies or intervals and using the same or different routes of administration.

[0063] cationic lipids

[0064] Cationic lipids are lipids that have a net positive charge at a selected pH. Cationic lipids typically consist of a charged hydrophilic head group and a hydrophobic tail.

[0065] In some embodiments, the cationic lipid is a cationic lipid having an amine head group. The amine head group can be a primary amine, secondary amine, or tertiary amine. The cationic lipid may contain one (monoamine) or more (polyamine) such amine groups.

[0066] In some embodiments, the cationic lipids are positively charged at pH values ​​below their pKa. In some embodiments, the cationic lipids are neutral, i.e., when the pH is equal to or higher than their pKa. In some embodiments, the cationic lipids are positively charged at acidic pH values ​​(i.e., pH 1.0 to pH 6.9). In some embodiments, the cationic lipids are neutral at certain pH values ​​(i.e., around physiological pH values ​​(pH 7.0 to pH 7.5)). Cationic lipids that can exist in a positively charged or neutral form depending on pH are generally referred to as ionizable lipids. In some embodiments, the cationic lipids are ionizable, and therefore they can exist in a positively charged or neutral form depending on pH.

[0067] In one embodiment, this disclosure relates to a cationic lipid represented by formula (I) or an isomer or salt thereof:

[0068] Formula (I), in: R1 and R2 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L7-R5 and -NR6R7; R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L6, and L7 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N, provided that when A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or S, one of R1 or R2 does not exist; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0069] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

[0070] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 2-26 C 2-22 and C 2-20 Alkenyl group.

[0071] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 2-26 C 2-22 and C 2-20 Alkyne group.

[0072] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 1-26 C 1-22 and C 1-20 alkyl.

[0073] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are each independently optional substituted branched or unbranched C. 1-17 alkyl.

[0074] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from -(CH2). m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26, 0 to 24, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0075] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently selected from -(CH2). m -A-(CH2) n -(CH3) y , where each of m, n and y is an integer in the range of 0 to 26, 0 to 24, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0076] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are independently -CH((CH2)). m -A-(CH2) n -(CH3) y)2, and each of m, n and y is independently an integer in the range of 0 to 26, 0 to 22, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0077] In some embodiments of the cationic lipid represented by formula (I), R3 and R4 are each independently -CH((CH2)). m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 8 or 0 to 10.

[0078] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-.

[0079] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-.

[0080] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -C(O)O- or -OC(O)-.

[0081] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -C(O)O-.

[0082] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -OC(O)-.

[0083] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -C(O)NH- or -NHC(O)-.

[0084] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -C(O)NH-.

[0085] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -C(S)NH- or -NHC(S)-.

[0086] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -C(S)NH-.

[0087] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -C(S)O- or -OC(S)-.

[0088] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -C(S)O-.

[0089] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -OC(O)NH- or -NHC(O)O-.

[0090] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -OC(O)NH-.

[0091] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are each independently -OP(O)(OH)O- or -OP(O)(O-)O-.

[0092] In some embodiments of the cationic lipid represented by formula (I), both X1 and X2 are -OP(O)(O-)O-.

[0093] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are -C(O)O- or -OC(O)- and -OP(O)(OH)O- or -OP(O)(O-)O-, respectively.

[0094] In some embodiments of the cationic lipid represented by formula (I), X1 and X2 are -OP(O)(OH)O- or -OP(O)(O-)O- and -C(O)O- or -OC(O)-, respectively.

[0095] In some embodiments of the cationic lipids represented by formula (I), each of L1, L2, L3, L4, L5, L6, and L7 is either absent or independently selected from optionally substituted C. 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

[0096] In some embodiments of the cationic lipid represented by formula (I), each of L1 and L2 is independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-3 Alkylene.

[0097] In some embodiments of the cationic lipid represented by formula (I), each of L1 and L2 is independently selected from optionally substituted C. 1-8 Alkylene.

[0098] In some embodiments of the cationic lipids represented by formula (I), each of L3 and L4 is independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-3 Alkylene.

[0099] In some embodiments of the cationic lipids represented by formula (I), each of L3 and L4 is independently selected from optionally substituted C. 1-5 and C 1-3 Alkylene.

[0100] In some embodiments of the cationic lipid represented by formula (I), each of L5 and L6 is independently absent.

[0101] In some embodiments of the cationic lipid represented by formula (I), each of L5 and L6 is independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-3 Alkylene.

[0102] In some embodiments of the cationic lipid represented by formula (I), each of L5 and L6 is independently selected from optionally substituted C. 1-5 and C 1-3 Alkylene.

[0103] In some embodiments of the cationic lipid represented by formula (I), L7 is either absent or optionally substituted with C. 1-10 C 1-8 C 1-6 C 1-4 Or C 1-3 Alkylene.

[0104] In some embodiments of the cationic lipid represented by formula (I), L7 is an optionally substituted C 1-5 Or C 1-3 Alkylene.

[0105] In some embodiments of the cationic lipid represented by formula (I), L7 is absent.

[0106] In some embodiments of the cationic lipid represented by formula (I), A is H, a bond, or a saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0107] In some embodiments of the cationic lipid represented by formula (I), A is H.

[0108] In some embodiments of the cationic lipid represented by formula (I), A is a bond.

[0109] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted saturated or unsaturated C. 3-10 C 3-8 Or C 3-6 Cycloalkyl.

[0110] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted saturated or unsaturated C. 3-6 Cycloalkyl.

[0111] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted saturated or unsaturated C containing 1-4 heteroatoms. 3-8 C 3-6 Or C 3-5 Heterocyclic alkyl groups.

[0112] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted saturated or unsaturated C containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

[0113] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted C containing 1-4 heteroatoms. 5-10 C 5-8 Or C 5-6 Mixed aromatic compounds.

[0114] In some embodiments of the cationic lipid represented by formula (I), A is an optionally substituted C containing 1-4 heteroatoms. 5-6 Mixed aromatic compounds.

[0115] In some embodiments of the cationic lipid represented by formula (I), A1 is , -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, S or N.

[0116] In some embodiments of the cationic lipid represented by formula (I), A1 is .

[0117] In some embodiments of the cationic lipid represented by formula (I), A1 is -CH2-.

[0118] In some embodiments of the cationic lipid represented by formula (I), A1 is -C(O)O-.

[0119] In some embodiments of the cationic lipid represented by formula (I), A1 is -C(O)NH-.

[0120] In some embodiments of the cationic lipid represented by formula (I), A1 is S.

[0121] In some embodiments of the cationic lipid represented by formula (I), A1 is N.

[0122] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from H, -OH, and optionally substituted C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L7-R5 and -NR6R7.

[0123] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from H and -OH.

[0124] In some embodiments of the cationic lipid represented by formula (I), both R1 and R2 are H.

[0125] In some embodiments of the cationic lipid represented by formula (I), both R1 and R2 are -OH.

[0126] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 alkyl.

[0127] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted C. 1-4C 1-3 and C 1-2 alkyl.

[0128] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted saturated or unsaturated C464. 3-10 C 3-8 and C 3-10 Cycloalkyl.

[0129] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted C. 6-10 C 6-8 and C 6-7 Aryl.

[0130] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted C atoms containing 1-4 heteroatoms. 3-10 C 3-8 and C 3-6 Heterocyclic alkyl groups.

[0131] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from optionally substituted C atoms containing 1-4 heteroatoms. 5-10 and C 5-8 Mixed aromatic compounds.

[0132] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from H and -O-L7-R5.

[0133] In some embodiments of the cationic lipid represented by formula (I), R1 is H and R2 is -O-L7-R5.

[0134] In some embodiments of the cationic lipid represented by formula (I), R1 is -O-L7-R5, and R2 is H.

[0135] In some embodiments of the cationic lipid represented by formula (I), R1 and R2 are independently selected from H and -NR6R7.

[0136] In some embodiments of the cationic lipid represented by formula (I), R1 is H and R2 is -NR6R7.

[0137] In some embodiments of the cationic lipid represented by formula (I), R1 is -NR6R7 and R2 is H.

[0138] In some embodiments of the cationic lipid represented by formula (I), R5, R6, and R7 are independently selected from H, -OH, and optionally substituted C.1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0139] In some embodiments of the cationic lipid represented by formula (I), R5 is H.

[0140] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 1-10 C 1-8 C 1-6 C 1-4 Or C 1-2 alkyl.

[0141] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 1-5 Or C 1-3 alkyl.

[0142] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 2-10 C 2-8 C 2-6 C 2-4 Or C2 alkenyl.

[0143] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 2-5 Or C 2-3 Alkenyl group.

[0144] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 2-10 C 2-8 C 2-6 C 2-4 Or C2 acetylene group.

[0145] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C 2-5 Or C 2-3 Alkyne group.

[0146] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted saturated or unsaturated C. 3-10 C 3-8 Or C 3-6 Cycloalkyl.

[0147] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted saturated or unsaturated C. 3-6 Cycloalkyl.

[0148] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted saturated or unsaturated C4 containing 1-4 heteroatoms. 3-10 C 3-8 Or C 3-6 Heterocyclic alkyl groups.

[0149] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted saturated or unsaturated C4 containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

[0150] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C containing 1-4 heteroatoms. 5-10 C 5-8 Or C 5-6 Mixed aromatic compounds.

[0151] In some embodiments of the cationic lipid represented by formula (I), R5 is an optionally substituted C containing 1-4 heteroatoms. 5-6 Mixed aromatic compounds.

[0152] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from H and -OH.

[0153] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 alkyl.

[0154] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C. 1-5 and C 1-3 alkyl.

[0155] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C. 2-10 C 2-8 C 2-6 C 2-4 And C2 alkenyl.

[0156] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C.2-5 and C 2-3 Alkenyl group.

[0157] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C. 2-10 C 2-8 C 2-6 C 2-4 and C2 acetylene group.

[0158] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are each independently selected from optionally substituted C. 2-5 and C 2-3 Alkyne group.

[0159] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted saturated or unsaturated C64-C ... 3-10 C 3-8 and C 3-6 Cycloalkyl.

[0160] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are each independently an optionally substituted saturated or unsaturated C. 3-6 Cycloalkyl.

[0161] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C. 6-10 C 6-8 and C 6-7 Aryl.

[0162] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted saturated or unsaturated C64-containing heteroatoms. 3-10 C 3-8 and C 3-6 Heterocyclic alkyl groups.

[0163] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are each independently a saturated or unsaturated C14 containing 1-4 heteroatoms, which are optionally substituted. 3-6 Heterocyclic alkyl groups.

[0164] In some embodiments of the cationic lipid represented by formula (I), R6 and R7 are independently selected from optionally substituted C atoms containing 1-4 heteroatoms. 5-10 C 5-8 C 5-7 and C 5-6 Mixed aromatic compounds.

[0165] In some embodiments, this disclosure relates to a cationic lipid represented by formula (II) or an isomer or salt thereof:

[0166] Equation (II), in: R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; (R 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L7, and L8 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide or C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Z is -CH2-, O, N, or S; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0167] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

[0168] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 2-26 C 2-22 and C 2-20 Alkenyl group.

[0169] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 2-26 C 2-22 and C 2-20 Alkyne group.

[0170] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently selected from optionally substituted branched or unbranched C. 1-26 C 1-22 and C 1-20 alkyl.

[0171] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently optional substituted branched or unbranched C. 1-17 alkyl.

[0172] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are independently selected from -(CH2). m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26, 0 to 24, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0173] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are each independently -(CH2). m -A-(CH2) n -(CH3) y , where each of m, n and y is an integer in the range of 0 to 26, 0 to 24, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0174] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are each independently -CH((CH2)). m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26, 0 to 24, 0 to 20, 0 to 18, 0 to 16, 0 to 14 or 0 to 12.

[0175] In some embodiments of the cationic lipid represented by formula (II), R3 and R4 are each independently -CH((CH2)). m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 10 or 0 to 8.

[0176] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-.

[0177] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -C(O)O- or -OC(O)-.

[0178] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -C(O)O-.

[0179] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -OC(O)-.

[0180] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -C(O)NH- or -NHC(O)-.

[0181] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -C(O)NH-.

[0182] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -C(S)NH- or -NHC(S)-.

[0183] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -C(S)NH-.

[0184] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -C(S)O- or -OC(S)-.

[0185] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -C(S)O-.

[0186] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -OC(O)NH- or -NHC(O)O-.

[0187] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -OC(O)NH-.

[0188] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are each independently -OP(O)(OH)O- or -OP(O)(O-)O-.

[0189] In some embodiments of the cationic lipid represented by formula (II), both X1 and X2 are -OP(O)(O-)O-.

[0190] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are -C(O)O- or -OC(O)- and -OP(O)(OH)O- or -OP(O)(O-)O-, respectively.

[0191] In some embodiments of the cationic lipid represented by formula (II), X1 and X2 are -OP(O)(OH)O- or -OP(O)(O-)O- and -C(O)O- or -OC(O)-, respectively.

[0192] In some embodiments of the cationic lipids represented by formula (II), each of L1, L2, L3, L4, L5, L7, and L8 is either absent or independently selected from optionally substituted C. 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

[0193] In some embodiments of the cationic lipid represented by formula (II), each of L1 and L2 is independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-3 Alkylene.

[0194] In some embodiments of the cationic lipid represented by formula (II), each of L1 and L2 is independently selected from optionally substituted C. 1-8 Alkylene.

[0195] In some embodiments of the cationic lipid represented by formula (II), each of L3 and L4 is independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 Alkylene.

[0196] In some embodiments of the cationic lipid represented by formula (II), each of L3 and L4 is independently selected from optionally substituted C. 1-5 and C 1-3 Alkylene.

[0197] In some embodiments of the cationic lipid represented by formula (II), L5 is absent.

[0198] In some embodiments of the cationic lipid represented by formula (II), L5 is an optionally substituted C 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 Alkylene.

[0199] In some embodiments of the cationic lipid represented by formula (II), L5 is an optionally substituted C 1-5 and C 1-3 Alkylene.

[0200] In some embodiments of the cationic lipid represented by formula (II), L7 is absent.

[0201] In some embodiments of the cationic lipid represented by formula (II), L7 is an optionally substituted C 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 Alkylene.

[0202] In some embodiments of the cationic lipid represented by formula (II), L7 is an optionally substituted C 1-5 and C 1-3 Alkylene.

[0203] In some embodiments of the cationic lipid represented by formula (II), L8 is absent.

[0204] In some embodiments of the cationic lipid represented by formula (II), L8 is an optionally substituted C 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 Alkylene.

[0205] In some embodiments of the cationic lipid represented by formula (II), L8 is an optionally substituted C 1-5 and C 1-3 Alkylene.

[0206] In some embodiments of the cationic lipid represented by formula (II), A is H, a bond, or a saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms5-10 Mixed aromatic compounds.

[0207] In some embodiments of the cationic lipid represented by formula (II), A is H.

[0208] In some embodiments of the cationic lipid represented by formula (II), A is a bond.

[0209] In some embodiments of the cationic lipid represented by formula (II), A is optionally substituted saturated or unsaturated C. 3-10 C 3-8 Or C 3-6 Cycloalkyl.

[0210] In some embodiments of the cationic lipid represented by formula (II), A is optionally substituted saturated or unsaturated C. 3-6 Cycloalkyl.

[0211] In some embodiments of the cationic lipid represented by formula (II), A is an optionally substituted saturated or unsaturated C containing 1-4 heteroatoms. 3-10 C 3-8 Or C 3-6 Heterocyclic alkyl groups.

[0212] In some embodiments of the cationic lipid represented by formula (II), A is an optionally substituted saturated or unsaturated C containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

[0213] In some embodiments of the cationic lipid represented by formula (II), A is an optionally substituted C containing 1-4 heteroatoms. 5-10 C 5-8 Or C 5-7 Mixed aromatic compounds.

[0214] In some embodiments of the cationic lipid represented by formula (II), A is an optionally substituted C containing 1-4 heteroatoms. 5-6 Mixed aromatic compounds.

[0215] In some embodiments of the cationic lipid represented by formula (II), A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, S or N.

[0216] In some embodiments of the cationic lipid represented by formula (II), A1 is -CH2-.

[0217] In some embodiments of the cationic lipid represented by formula (II), A1 is -C(O)O-.

[0218] In some embodiments of the cationic lipid represented by formula (II), A1 is -C(O)NH-.

[0219] In some embodiments of the cationic lipid represented by formula (II), A1 is S.

[0220] In some embodiments of the cationic lipid represented by formula (II), A1 is N.

[0221] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q Independently selected from H, -OH, -CH2OH, or optionally substituted C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 The terms are heteroaryl, -O-L7-R5, and -NR6R7, where q is an integer in the range of 0 to 4.

[0222] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q The q is independently selected from H and -OH, where q is an integer in the range of 0 to 4.

[0223] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q H is a variable where q is an integer in the range of 0 to 4.

[0224] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is -OH, where q is an integer in the range of 0 to 4.

[0225] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is -OH, -CH2OH, or both, where q is an integer in the range of 0 to 4.

[0226] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q C is an optional substitute 1-10 C 1-8 C 1-6 C 1-4and C 1-2 Alkyl group, where q is an integer in the range of 0 to 4.

[0227] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q C is an optional substitute 1-4 C 1-3 and C 1-2 Alkyl group, where q is an integer in the range of 0 to 4.

[0228] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is either a saturated or unsaturated C that can be substituted by any choice. 3-10 C 3-8 and C 3-6 Cycloalkyl, where q is an integer in the range of 0 to 4.

[0229] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q C is an optional substitute 6-10 C 6-8 and C 6-7 Aryl, where q is an integer in the range of 0 to 4.

[0230] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is an optional substituted C containing 1-4 heteroatoms 3-10 C 3-8 Or C 3-6 Heterocyclic alkyl groups, where q is an integer in the range of 0 to 4.

[0231] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is an optional substituted C containing 1-4 heteroatoms 5-10 Or C 5-8 A heteroaryl group, where q is an integer in the range of 0 to 4.

[0232] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is -O-L8-R5, where q is an integer in the range of 0 to 4.

[0233] In some embodiments of the cationic lipid represented by formula (II), (R 10 ) q It is -NR6R7, where q is an integer in the range of 0 to 4.

[0234] In some embodiments of the cationic lipid represented by formula (II), q is an integer in the range of 0 to 4, 0 to 3, 0 to 2, or 0 to 1.

[0235] In some embodiments of the cationic lipid represented by formula (II), Z is -CH2-, O, N, or S.

[0236] In some embodiments of the cationic lipid represented by formula (II), Z is -CH2-.

[0237] In some embodiments of the cationic lipid represented by formula (II), Z is O.

[0238] In some embodiments of the cationic lipid represented by formula (II), Z is N.

[0239] In some embodiments of the cationic lipid represented by formula (II), Z is S.

[0240] In some embodiments of the cationic lipid represented by formula (II), R5, R6, and R7 are independently selected from H, -OH, and optionally substituted C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0241] In some embodiments of the cationic lipid represented by formula (II), R5 is H.

[0242] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 1-10 C 1-8 C 1-6 C 1-4 Or C 1-2 alkyl.

[0243] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 1-5 Or C 1-3 alkyl.

[0244] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 2-10 C 2-8 C 2-6 C2-4 Or C2 alkenyl.

[0245] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 2-5 Or C 2-3 Alkenyl group.

[0246] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 2-10 C 2-8 C 2-6 C 2-4 Or C2 acetylene group.

[0247] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 2-5 Or C 2-3 Alkyne group.

[0248] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted saturated or unsaturated C 3-10 C 3-8 Or C 3-6 Cycloalkyl.

[0249] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted saturated or unsaturated C 3-6 Cycloalkyl.

[0250] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C 6-10 C 6-8 Or C 6-7 Aryl.

[0251] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted saturated or unsaturated C4 containing 1-4 heteroatoms. 3-10 C 3-8 Or C 3-6 Heterocyclic alkyl groups.

[0252] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted saturated or unsaturated C4 containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

[0253] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C containing 1-4 heteroatoms. 5-10 C 5-8 Or C 5-6 Mixed aromatic compounds.

[0254] In some embodiments of the cationic lipid represented by formula (II), R5 is an optionally substituted C containing 1-4 heteroatoms. 5-6 Mixed aromatic compounds.

[0255] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from H and -OH.

[0256] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 1-10 C 1-8 C 1-6 C 1-4 and C 1-2 alkyl.

[0257] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 1-5 and C 1-3 alkyl.

[0258] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 2-10 C 2-8 C 2-6 C 2-4 And C2 alkenyl.

[0259] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 2-5 and C 2-3 Alkenyl group.

[0260] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 2-10 C 2-8 C 2-6 C 2-4 and C2 acetylene group.

[0261] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 2-5 and C 2-3 Alkyne group.

[0262] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted saturated or unsaturated C6. 3-10 C 3-8 and C 3-6 Cycloalkyl.

[0263] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are each independently an optionally substituted saturated or unsaturated C. 3-6 Cycloalkyl.

[0264] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C. 6-10 C 6-8 and C 6-7 Aryl.

[0265] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted saturated or unsaturated C64-containing heteroatoms. 3-10 C 3-8 and C 3-6 Heterocyclic alkyl groups.

[0266] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted saturated or unsaturated C64-containing heteroatoms. 3-6 Heterocyclic alkyl groups.

[0267] In some embodiments of the cationic lipid represented by formula (II), R6 and R7 are independently selected from optionally substituted C atoms containing 1-4 heteroatoms. 5-10 C 5-8 and C 5-6 Mixed aromatic compounds.

[0268] In some embodiments, the cationic lipid represented by formula (I) or formula (II) is substituted with a substituent independently selected from H, -OH, Cl, Br, I, O, S, N, P, and optionally substituted C. 1-6 Alkoxy, optional substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 Alkyne group, optionally substituted saturated or unsaturated C 3-10 cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted saturated or unsaturated C-type compounds containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or optionally substituted C groups containing 1-4 heteroatoms 5-10 heteroaryl groups or combinations thereof.

[0269] In some embodiments, the N:P ratio or the ratio of cationic lipids to nucleic acids in the LNP formulation is between 1 and 18, between 1 and 17, between 1 and 16, between 1 and 15, between 1 and 14, between 1 and 13, between 1 and 12, between 1 and 11, between 1 and 10, between 1 and 9, between 1 and 8, between 1 and 7, between 1 and 6, between 1 and 5, between 1 and 4, between 1 and 3, between 1 and 2, or any range thereof.

[0270] In some embodiments, the N:P ratio or the ratio of cationic lipids to nucleic acids in the LNP formulation is about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, about 1, or any part or fraction thereof.

[0271] The proportion of cationic lipids in the lipid nanoparticle composition is from about 10 mol% to about 70 mol%, from about 10 mol% to about 65 mol%, from about 10 mol% to about 60 mol%, from about 10 mol% to about 55 mol%, from about 10 mol% to about 50 mol%, or any range thereof. In some embodiments, the cationic lipids in the lipid nanoparticle composition are from about 10 mol%, from about 11 mol%, from about 12 mol%, from about 13 mol%, from about 14 mol%, from about 15 mol%, from about 16 mol%, from about 17 mol%, from about 18 mol%, from about 19 mol%, from about 20 mol%, from about 21 mol%, from about 22 mol%, from about 23 mol%, from about 24 mol%, from about 25 mol%, from about 26 mol%, from about 27 mol%, from about 28 mol%, from about 29 mol%, from about 30 mol%, from about 31 mol%, from about 32 mol%, from about 33 mol%, from about 34 mol%, from about 35 mol%, from about 36 mol%, from about 37 mol%, from about 38 mol%. Approximately 39 mol%, approximately 40 mol%, approximately 41 mol%, approximately 42 mol%, approximately 43 mol%, approximately 44 mol%, approximately 45 mol%, approximately 46 mol%, approximately 47 mol%, approximately 48 mol%, approximately 49 mol%, approximately 50 mol%, approximately 51 mol%, approximately 52 mol%, approximately 53 mol%, approximately 54 mol%, approximately 55 mol%, approximately 56 mol%, approximately 57 mol%, approximately 58 mol%, approximately 59 mol%, approximately 60 mol%, approximately 61 mol%, approximately 62 mol%, approximately 63 mol%, approximately 64 mol%, approximately 65 mol%, approximately 66 mol%, approximately 67 mol%, approximately 68 mol%, approximately 69 mol%, approximately 70 mol%, or any part or fraction thereof.

[0272] In some embodiments, the cationic lipids of this disclosure comprise one of the structures described in Table 1, including its isomers and salts.

[0273] Table 1: Cationic Lipids

[0274] The following general reaction scheme-I illustrates an exemplary method for synthesizing cationic lipids represented by formula (I) or their isomers or salts:

[0275] Formula (I), R1, R2, R3, R4, X1, X2, L1, L2, L3, L4, L5, L6, A, and A1 are the same as those described herein. It should be understood that those skilled in the art may be able to prepare these cationic lipids by similar methods or by combining other methods known to them. It should also be understood that, by using appropriate key starting materials and modifying the synthesis parameters as needed, those skilled in the art can prepare other cationic lipids of formula (I) not specifically described herein in a manner similar to that described below. Generally, key starting materials can be obtained from sources such as BLD pharm, Angene Chemical, SigmaAldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and FluorochemUSA, or synthesized from sources known to those skilled in the art (see, for example, *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition (Wiley, December 2000); Smith, Michael B., *Compendium of Organic Synthetic Methods*, Vol. 13, 2014, John Wiley & Sons, Inc.), or synthesized as described herein. During synthesis, it may be necessary and / or desirable to protect sensitive or reactive groups on any molecule of interest. This can be achieved using standard techniques known to those skilled in the art (see, for example, Wuts, Peter GM, *Greene's Protective Groups in Organic Synthesis*, 5th edition, 2014, John Wiley & Sons, Inc.).

[0276] General Reaction Scheme-I

[0277] In some embodiments, cationic lipids represented by formula (I) (e.g., cationic lipid formula (Ia)) can be prepared according to general reaction scheme -I, wherein: X is a halogen atom selected from Cl, Br, I or F.

[0278] Step 1: Key starting material-9 (KSM-9) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of KSM-9, 4-toluenesulfonyl chloride, and triethylamine can be stirred at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-11 after any necessary post-processing and / or purification steps.

[0279] Step 2: Key Starting Material-10 (KSM-10) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of KSM-10, 4-toluenesulfonyl chloride, and triethylamine can be stirred at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-12 after any necessary post-processing and / or purification steps.

[0280] Step 3: Key starting material-8 (KSM-8) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of Cs2CO3, KSM-8, and intermediate-12 can be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-13 after any necessary post-processing and / or purification steps.

[0281] Step 4: Intermediate-13 may be treated with TFA at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-14 after any necessary post-processing and / or purification steps.

[0282] Step 5: The mixture of Cs2CO3, intermediate-14 and intermediate-11 may be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-15 after any necessary post-processing and / or purification steps.

[0283] Step 6: Intermediate-15 may be treated with TFA at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-16 after any necessary post-processing and / or purification steps.

[0284] Step 7: Intermediate-1 may be obtained from commercial sources or synthesized according to methods known to those skilled in the art or according to step 1 of General Reaction Scheme II. A mixture of intermediate-16, intermediate-1, K2CO3, Cs2CO3, and KI may be stirred and heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-17 after any necessary post-treatment and / or purification steps.

[0285] Step 8: Intermediate-2 may be obtained from commercial sources or synthesized according to methods known to those skilled in the art or according to step 2 of General Reaction Scheme II. A mixture of intermediate-17, intermediate-2, K2CO3, Cs2CO3 and KI may be stirred and heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain the cationic lipid of formula (Ia) after any necessary post-treatment and / or purification steps.

[0286] The following general reaction schemes-II and-III illustrate exemplary methods for synthesizing cationic lipids represented by formula (II) or their isomers or salts:

[0287] Equation (II), Among them, R3, R4, R 10X1, X2, L1, L2, L3, L4, L5, L7, A, A1, and Z are the same as those described herein. It should be understood that those skilled in the art may be able to prepare these cationic lipids by similar methods or by combining other methods known to them. It should also be understood that, by using appropriate key starting materials and modifying the synthesis parameters as needed, those skilled in the art can prepare other cationic lipids of formula (II) not specifically described herein in a manner similar to that described below. Generally, key starting materials can be obtained from sources such as BLD pharm, Angene Chemical, SigmaAldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and FluorochemUSA, or synthesized from sources known to those skilled in the art (see, for example, *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition (Wiley, December 2000); Smith, Michael B., *Compendium of Organic Synthetic Methods*, Vol. 13, 2014, John Wiley & Sons, Inc.), or synthesized as described herein. During synthesis, it may be necessary and / or desirable to protect sensitive or reactive groups on any molecule of interest. This can be achieved using standard techniques known to those skilled in the art (see, for example, Wuts, Peter GM, *Greene's Protective Groups in Organic Synthesis*, 5th edition, 2014, John Wiley & Sons, Inc.).

[0288] General Reaction Scheme II

[0289] In some embodiments, cationic lipids represented by formula (II) (e.g., compound formula (IIa)) can be prepared according to general reaction scheme-II, wherein: X is a halogen atom selected from Cl, Br, I or F; P is a protecting group, such as acetyl (Ac).

[0290] Step 1: Key starting material-1 (KSM-1) and key starting material-2 (KSM-2) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of KSM-1 and KSM-2 can be treated at room temperature with DCC and DMAP for a sufficient time known to those skilled in the art to obtain intermediate-1 after any necessary post-processing and / or purification steps.

[0291] Step 2: Key starting material-3 (KSM-3) and key starting material-4 (KSM-4) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of KSM-3 and KSM-4 can be treated at room temperature with DCC and DMAP for a sufficient time known to those skilled in the art to obtain intermediate-2 after any necessary post-processing and / or purification steps.

[0292] Step 3: Key starting material-5 (KSM-5) can be purchased from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of intermediate-1, K2CO3, Cs2CO3, KI and KSM-5 can be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-3 after any necessary post-processing and / or purification steps.

[0293] Step 4: The mixture of intermediate-3, K2CO3, Cs2CO3, KI and intermediate-2 may be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-4 after any necessary post-processing and / or purification steps.

[0294] Step 5: Key starting material-6 (KSM-6) can be purchased from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of intermediate-4, KSM-6, and a Lewis acid (e.g., BF3·Et2O) can be stirred at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-5 after any necessary post-processing and / or purification steps.

[0295] Step 6: Intermediate-5 can be treated with NH3 in MeOH at room temperature and stirred for a sufficient time known to those skilled in the art to obtain the cationic lipid of formula (IIa) after any necessary post-treatment and / or purification steps.

[0296] General Reaction Scheme III

[0297] In some embodiments, the cationic lipid represented by formula (II) can be prepared according to general reaction scheme-III, wherein: X is a halogen atom selected from Cl, Br, I or F; P is a protecting group, such as benzyl (Bn).

[0298] Step 1: Key starting material-7 (KSM-7) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of KSM-7, 4-toluenesulfonyl chloride, and triethylamine can be stirred at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-6 after any necessary post-processing and / or purification steps.

[0299] Step 2: Key starting material-8 (KSM-8) can be obtained from commercial sources or synthesized according to methods known to those skilled in the art. A mixture of Cs2CO3, KSM-8, and intermediate-6 can be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-7 after any necessary post-processing and / or purification steps.

[0300] Step 3: Intermediate-7 can be treated with TFA at room temperature for a sufficient time known to those skilled in the art to obtain intermediate-8 after any necessary post-processing and / or purification steps.

[0301] Step 4: Intermediate-1 may be obtained from commercial sources or synthesized according to methods known to those skilled in the art or according to Step 1 of General Reaction Scheme II. A mixture of Intermediate-8, Intermediate-1, K2CO3, Cs2CO3, and KI may be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain Intermediate-9 after any necessary post-processing and / or purification steps.

[0302] Step 5: Intermediate-2 may be obtained from commercial sources or synthesized according to methods known to those skilled in the art or according to step 2 of General Reaction Scheme II. A mixture of intermediate-9, intermediate-2, K2CO3, Cs2CO3, and KI may be heated at an appropriate temperature for a sufficient time known to those skilled in the art to obtain intermediate-10 after any necessary post-processing and / or purification steps.

[0303] Step 6: The solution of intermediate-10 in ethanol can be degassed under a N2 atmosphere for a sufficient time known to those skilled in the art. Afterwards, Pd-C and AcOH can be added to the reaction mixture at room temperature, and the reaction mixture can be stirred under an H2 atmosphere for a sufficient time known to those skilled in the art to obtain the cationic lipid of formula (II) after any necessary post-treatment and / or purification steps.

[0304] The steps mentioned in General Reaction Schemes I, II and III are provided for reference only. Those skilled in the art will recognize that the individual steps, starting materials and reaction conditions (e.g., but not limited to reagents, solvents, catalysts, protecting groups, temperatures, etc.) can be modified or alternative chemicals other than those described herein can be used to obtain suitable intermediates or end products.

[0305] Other lipid components

[0306] Other lipid components of the lipid nanoparticle composition may include one or more lipids, such as phospholipids, sterols, and PEG-lipids.

[0307] Phospholipids

[0308] Phospholipids consist of lipids with a hydrophilic head containing a phosphate group and a hydrophobic tail consisting of fatty acid chains attached to a glycerol or sphingosine backbone.

[0309] Exemplary phospholipids used in the lipid nanoparticle compositions include, but are not limited to, 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), and 1,2-distearateoyl-sn-glycerol-3-phosphocholine (DSPC). PC), 1,2-diundecanoyl-sn-glycerol-3-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycerol-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholestylhemisuccinoyl-sn-glycerol-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphocholine (C16 Lyso PC), 1,2-dilinoyl-sn-glycerol-3-phosphate choline, 1,2-disarachidanoyl-sn-glycerol-3-phosphate choline, 1,2-docosahexaenoyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-diphydanoyl-sn-glycerol-3-phosphate ethanolamine (ME16.0) PE), 1,2-distearate-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-diarachidonicoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate racemic-(1 Sodium 1-(-glycerol) (DOPG), 1-myristoyl-2-stearoyl-sn-glycerol-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphocholine (PMPC), 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl-sn-glycerol-3-phosphocholine (SMPC), 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphocholine (SPPC), 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphocholine (SOPC), 1-stearoyl-2-docosahexaenoyl-sn-glycerol-3-phosphocholine (SDPC), sphingomyelin or combinations thereof.

[0310] The proportion of phospholipids present in the lipid nanoparticle composition is about 2 mol% to about 65 mol%, about 5 mol% to about 65 mol%, about 10 mol% to about 65 mol%, about 10 mol% to about 50 mol%, or any range thereof.

[0311] In some embodiments, the proportion of phospholipids present in the lipid nanoparticle composition is about 65 mol%, about 60 mol%, about 55 mol%, about 50 mol%, about 45 mol%, about 44 mol%, about 43 mol%, about 42 mol%, about 41 mol%, about 40 mol%, about 39 mol%, about 38 mol%, about 37 mol%, about 36 mol%, about 35 mol%, about 34 mol%, about 33 mol%, about 32 mol%, about 31 mol%, about 30 mol%, about 29 mol%, and about 28 mol%. Approximately 27 mol%, approximately 26 mol%, approximately 25 mol%, approximately 24 mol%, approximately 23 mol%, approximately 22 mol%, approximately 21 mol%, approximately 20 mol%, approximately 19 mol%, approximately 18 mol%, approximately 17 mol%, approximately 16 mol%, approximately 15 mol%, approximately 14 mol%, approximately 13 mol%, approximately 12 mol%, approximately 11 mol%, approximately 10 mol%, approximately 9 mol%, approximately 8 mol%, approximately 7 mol%, approximately 6 mol%, approximately 5 mol%, approximately 4 mol%, approximately 3 mol%, approximately 2 mol%, or any part or fraction thereof.

[0312] Sterols

[0313] The lipid nanoparticle compositions disclosed herein may include sterols and / or sterol derivatives. The term "sterol" as used herein includes, but is not limited to, cholesterol, sitosterol, fecosterol, ergosterol, campesterol, stigmasterol, or derivatives thereof. In some embodiments, the lipid nanoparticle compositions comprise cholesterol and / or cholesterol derivatives. Non-limiting examples of cholesterol and cholesterol derivatives include 5α-cholesterol, 5β-fecosterol, cholesterol-(2'-hydroxy)-ethyl ether, cholesterol-(4'-hydroxy)-butyl ether, 6-ketocholesterol, 5α-cholesterol, cholesterolenone, 5α-cholesterone, 5β-cholesterone, cholesterol decanoate, or mixtures thereof. Methods for preparing cholesterol and cholesterol derivatives are well known in the art.

[0314] The proportion of sterols present in the lipid nanoparticle composition is about 20 mol% to about 65 mol%, about 20 mol% to about 60 mol%, about 20 mol% to about 55 mol%, about 20 mol% to about 50 mol%, about 20 mol% to about 45 mol%, about 20 mol% to about 40 mol%, or any range thereof.

[0315] In some embodiments, the proportion of sterols present in the lipid nanoparticle composition is about 65 mol%, about 60 mol%, about 55 mol%, about 50 mol%, about 45 mol%, about 44 mol%, about 43 mol%, about 42 mol%, about 41 mol%, about 40 mol%, about 39 mol%, about 38 mol%, about 37 mol%, about 36 mol%, about 35 mol%, about 34 mol%, about 33 mol%, about 32 mol%, about 31 mol%, about 30 mol%, about 29 mol%, about 28 mol%, about 27 mol%, about 26 mol%, about 25 mol%, about 24 mol%, about 23 mol%, about 22 mol%, about 21 mol%, about 20 mol%, or any part or fraction thereof.

[0316] PEG-lipids

[0317] The terms "PEG-lipid," "polyethylene glycol-modified lipid," "PEG-linked lipid," "PEG-coupled lipid," "PEG-lipid conjugate," or "PEG-modified lipid" are used interchangeably to refer to polyethylene glycol linked to a lipid moiety. The lipid moiety may be directly linked to the PEG molecule or linked via a linker. In some embodiments, PEG-lipids include PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and / or PEG-modified cholesterol and / or mixtures thereof. Methods for preparing PEG-lipids are well known to those skilled in the art.

[0318] In some embodiments, the PEG-lipid is selected from, but not limited to, mPEG-dimyristoylglycerol (mPEG-DMG), mPEG-N,N-bistetradecylacetamide (mPEG-DTA or ALC0159), mPEG-cholesterol (mPEG-CLS), mPEG-DSPE, mPEG-DMPE, mPEG-DPPE, mPEG-DLPE, mPEG-DOPE, mPEG-DPPC, mPEG-DSPC, 1,2-distearate-sn-glycerol-3-phosphate ethanolamine with coupled methoxy polyethylene glycol (mPEG-DSPE), 1,2-dimyristoyl-racemic-glycerol-3-methoxy polyethylene glycol-2000 (mPEG2000-DMG), α-(3'-{[1,2-di(myristyloxy)propoxy]carbonylamino}propyl)-ω-methoxypolyoxyethylene (mPEG2000C-DMG), or mixtures thereof.

[0319] The PEG portion of the PEG-lipid may have an average molecular weight in the range of about 0.5 kDa to 10 kDa. In some embodiments, the average molecular weight of the PEG-lipid is about 0.5 kDa to 5 kDa, about 0.5 kDa to 4 kDa, about 0.5 kDa to 3 kDa, about 0.5 kDa to 2 kDa, or any range thereof. In some embodiments, the average molecular weight of the PEG-lipid is about 0.5 kDa to about 2 kDa.

[0320] The proportion of PEG-lipids present in the lipid nanoparticle composition may be from about 0.2 mol% to about 2.0 mol%, from about 0.2 mol% to about 1.9 mol%, from about 0.2 mol% to about 1.8 mol%, from about 0.2 mol% to about 1.7 mol%, from about 0.2 mol% to about 1.6 mol%, from about 0.2 mol% to about 1.5 mol%, or any range thereof.

[0321] In some embodiments, the proportion of PEG-lipids present in the lipid nanoparticle composition is about 2.0 mol%, about 1.9 mol%, about 1.8 mol%, about 1.7 mol%, about 1.6 mol%, about 1.5 mol%, about 1.4 mol%, about 1.3 mol%, about 1.2 mol%, about 1.1 mol%, about 1.0 mol%, about 0.9 mol%, about 0.8 mol%, about 0.7 mol%, about 0.6 mol%, about 0.5 mol%, about 0.4 mol%, about 0.3 mol%, about 0.2 mol%, or any part or fraction thereof.

[0322] The lipid nanoparticle composition comprising the cationic lipid represented by formula (I) or formula (II) may optionally comprise an ionizable polymer.

[0323] Ionizable polymers

[0324] As used herein, the term "polymer" refers to a compound formed from a plurality of repeating units called monomers. Polymers are produced through a process called polymerization, in which two or more monomers are linked by chemical bonds to form the polymer. In some embodiments, the polymer is branched or unbranched. In some embodiments, the polymer can be a homopolymer, i.e., composed of the same type of repeating units or monomers, or a heteropolymer, i.e., composed of more than one type of repeating units or monomers. The terms heteropolymer and copolymer are used interchangeably herein.

[0325] As used herein, the term "ionizable polymer" means a polymer that exists in a positively charged or neutral form depending on the pH of the solution or environment. For example, when the pH of the solution is below the pKa of the ionizable polymer, the polymer will be cationic (positively charged), and when the pH of the solution is equal to or higher than the pKa of the ionizable polymer, it will be neutral (uncharged). In some embodiments, the ionizable polymer is positively charged at acidic pH (i.e., pH 1.0 to pH 6.9). In some embodiments, the ionizable polymer is neutral (uncharged) near physiological pH (pH 7.0 to pH 7.5).

[0326] In some embodiments, the ionizable polymer is a biocompatible polymer or a biodegradable polymer. The terms "biocompatible polymer" and "biodegradable polymer" are used interchangeably, meaning a polymer that has substantially no harmful effects when introduced into a living or biological system. Such a polymer is capable of degradation when introduced into a living or biological system and is not expected to produce significant toxicity or immune responses.

[0327] In some embodiments, the lipid nanoparticle composition comprises an ionizable polymer. The ionizable polymer may be selected from chitosan, chitosan derivatives, cellulose derivatives, poly-L-lysine (PLL), protamine, polyethyleneimine, derivatives thereof, or combinations thereof.

[0328] In some embodiments, the ionizable polymer is positively charged at acidic pH (i.e., pH 1.0 to 6.9) and neutral near physiological pH (pH 7.0 to 7.5).

[0329] The proportion of the ionizable polymer present in the lipid nanoparticle composition can be from about 1 mol% to about 25 mol%.

[0330] In some embodiments, preferred ionizable polymers include chitosan, chitosan derivatives, cellulose derivatives, or combinations thereof.

[0331] Lipid nanoparticles (LNPs) or lipid nanoparticle (LNP) compositions or formulations

[0332] The lipid nanoparticles or lipid nanoparticle compositions described herein typically comprise cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids represented by formula (I) or formula (II).

[0333] In some respects, the lipid nanoparticle composition comprises cationic lipids, ionizable polymers, phospholipids, sterols, PEG-lipids, and nucleic acids represented by formula (I) or formula (II).

[0334] In some respects, this document discloses a lipid nanoparticle composition comprising cationic lipids, nucleic acids, biocompatible polymers, cationic lipids, phospholipids, sterols, and PEG-lipids represented by formula (I) or formula (II).

[0335] In some respects, the lipid nanoparticles or lipid nanoparticle compositions described herein comprise cationic lipids, phospholipids, sterols, and PEG-lipids represented by formula (I) or formula (II).

[0336] In some respects, the lipid nanoparticles or lipid nanoparticle compositions described herein comprise cationic lipids, phospholipids, sterols, and PEG-lipids represented by formula (I) or formula (II).

[0337] In some respects, this article discloses a lipid nanoparticle composition comprising, in amounts from 10 mol% to 70 mol% of, cationic lipids, phospholipids, sterols, PEG-lipids and nucleic acids represented by formula (I) or formula (II).

[0338] In some respects, this article discloses a lipid nanoparticle composition comprising, in amounts of 10 mol% to 70 mol% of a cationic lipid represented by formula (I) or formula (II), in amounts of 2 mol% to 65 mol% of phospholipids, sterols, PEG-lipids and nucleic acids.

[0339] In some respects, this article discloses a lipid nanoparticle composition comprising, in amounts of 10 mol% to 70 mol% of a cationic lipid represented by formula (I) or formula (II), in amounts of 2 mol% to 65 mol% of a phospholipid, in amounts of 20 mol% to 65 mol% of a sterol, a PEG-lipid, and a nucleic acid.

[0340] In some respects, this article discloses a lipid nanoparticle composition comprising 10 mol% to 70 mol% of a cationic lipid represented by formula (I) or formula (II), 2 mol% to 65 mol% of a phospholipid, 20 mol% to 65 mol% of a sterol, 0.2 mol% to 2.0 mol% of a PEG-lipid and a nucleic acid.

[0341] In some respects, this article discloses a lipid nanoparticle composition comprising, in amounts of 10 mol% to 70 mol% of a cationic lipid represented by formula (I) or formula (II), in amounts of 2 mol% to 65 mol% of a phospholipid, in amounts of 20 mol% to 65 mol% of a sterol, in amounts of 0.2 mol% to 2.0 mol% of a PEG-lipid, in amounts of 1 mol% to 25 mol% of an ionizable polymer and a nucleic acid.

[0342] In some embodiments, this disclosure relates to a composition comprising the lipid nanoparticles described herein and a pharmaceutically acceptable carrier or excipient, such as, but not limited to, buffers, stabilizers, tension modifiers, surfactants, chelating agents, salts, antioxidants, diluents and / or preservatives or combinations thereof.

[0343] In some embodiments, the lipid to nucleic acid ratio or N:P ratio in the lipid nanoparticle composition or formulation is between 1 and 18, between 1 and 17, between 1 and 16, between 1 and 15, between 1 and 14, between 1 and 13, between 1 and 12, between 1 and 11, between 1 and 10, between 1 and 9, between 1 and 8, between 1 and 7, between 1 and 6, between 1 and 5, between 1 and 4, between 1 and 3, between 1 and 2, or any range thereof.

[0344] In some embodiments, the lipid to nucleic acid ratio or N:P ratio in the lipid nanoparticle composition or formulation is about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, about 1, or any part or fraction thereof.

[0345] In some embodiments, this disclosure relates to a method of delivering nucleic acids, the method comprising applying a lipid nanoparticle composition of the present disclosure, the composition comprising nucleic acids, cationic lipids represented by formula (I) or formula (II), phospholipids, sterols, and PEG-lipids.

[0346] In some embodiments, this disclosure relates to a method of delivering nucleic acids, the method comprising applying a lipid nanoparticle composition of the present disclosure, the composition comprising nucleic acids, cationic lipids represented by formula (I) or formula (II), phospholipids, sterols, PEG-lipids, and ionizable polymers.

[0347] In some embodiments, this disclosure relates to a method of treating or preventing a disease, the method comprising administering a lipid nanoparticle composition to a subject in need, the composition comprising cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids represented by formula (I) or formula (II).

[0348] In some embodiments, this disclosure relates to a method of treating or preventing a disease, the method comprising administering a lipid nanoparticle composition to a subject in need, the composition comprising cationic lipids, phospholipids, sterols, PEG-lipids, ionizable polymers, and nucleic acids represented by formula (I) or formula (II).

[0349] In some embodiments, this disclosure relates to the use of lipid nanoparticle compositions in the preparation of medicaments for treating or preventing disease in subjects, said compositions comprising cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids represented by formula (I) or formula (II).

[0350] In some embodiments, this disclosure relates to the use of lipid nanoparticle compositions in the preparation of medicaments for treating or preventing disease in subjects, said compositions comprising cationic lipids, phospholipids, sterols, PEG-lipids, ionizable polymers, and nucleic acids represented by formula (I) or formula (II).

[0351] The lipid nanoparticle compositions described herein can be used as a platform for the therapeutic or prophylactic delivery of nucleic acids. The nucleic acids may encode one or more antigens, one or more proteins, one or more antibodies, or combinations thereof. The nucleic acids may regulate or modulate cellular function. The nucleic acids may belong to any organism, such as prokaryotes or eukaryotes, single-celled organisms, multicellular organisms, viruses, bacteria, mycoplasma, protozoa, animals, or humans.

[0352] In some embodiments, the lipid nanoparticle composition can be used to treat or prevent diseases, such as, but not limited to: Belonging to, for example, the family Microribonucleoviridae ( Picornaviride ), Caliciviridae ( Calciviridae ), Astroviridae ( Astroviridae ), Clothviridae ( Togaviridae Flaviviridae ( Flaviviridae Coronavirus family ( Coronaviridae Arteritis Virology Department ( Arteriviridae ), Rhabdoviridae ( Rhabndoviridae Filoviridae ( Filoviridae ), Paramyxoviridae ( Paramyxoviridae ), Bonaviridae ( Bornaviridae Orthomyxoviridae ( Orthomyxoviridae Bunyaviridae ( Bunyaviridae ), Arenaviridae ( Arenaviridae ), Reoviridae ( Reoviridae Retroviridae ( Retroviridae ), Polyomaviridae ( Polyomaviridae Herpesviridae ( Herpesviridae ), Poxviridae ( Poxviridae ), Papillomavirus Family ( Papillomaviridae ), Pepadnaviridae Adenoviridae ( Adenoviridae Parvoviridae ( Parvoviridae Hepatitis E Virology ( ) Hepeviridae ), Porconiidae (Circoviridae Diseases caused by viruses or combinations thereof.

[0353] Belonging to, for example, the genus Bacillus ( Bacillus Bordetella spp. Bordetella ), genus *Borrelia* Borrelia Brucella ( ) Brucella ), Campylobacter spp. Campylobacter Chlamydia ( ) Chlamydia Clostridium ( Clostridium Corynebacterium spp. Corynebacterium ), Enterococcus ( Enterococcus Escherichia coli spp. Escherichia Haemophilus spp. Haemophilus ), Helicobacter spp. Helicobacter Legionella ( ) Legionella Leptospira ( ) Leptospira Listeria ( ) Listeria ), Mycobacterium ( Mycobacterium Mycoplasma genus Mycoplasma ), Neisseria spp. Neisseria ), Pseudomonas spp. Pseudomonas ), Rickettsia species ( Rickettsia Salmonella ( Salmonella ), Shigella spp. Shigella Staphylococcus spp. Staphylococcus Streptococcus ( Streptococcus ), Vibrio genus ( Vibrio Yersinia spp. Yersinia Diseases caused by bacteria or combinations thereof.

[0354] Cancers such as bladder cancer, breast cancer, colorectal cancer, endometrial cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, or thyroid cancer.

[0355] Nucleic acid

[0356] As used herein, the term "nucleic acid" refers to a polymer containing two or more nucleotides, such as deoxyribonucleotides or ribonucleotides, in unmodified or modified form. The nucleic acid may be single-stranded or double-stranded, linear or circular.

[0357] As used in this article, the term "nucleotide" refers to either ribonucleotide or deoxyribonucleotide. In the context of RNA, the term nucleotide refers to ribonucleotide, and in the context of DNA, it refers to deoxyribonucleotide.

[0358] The terms “ribonucleic acid” or “RNA” are used interchangeably in this document and refer to a polymer of ribonucleotides. RNA can be single-stranded or double-stranded, linear or circular. The term RNA also includes messenger RNA (mRNA) and non-coding RNA (ncRNA).

[0359] The terms “deoxyribonucleic acid” or “DNA” are used interchangeably in this document and refer to a polymer of deoxyribonucleotides. DNA can be single-stranded or double-stranded, linear or circular.

[0360] In some embodiments, the nucleic acid encodes an antigen, such as, but not limited to, those derived from cholera toxoid, tetanus toxoid, diphtheria toxoid, hepatitis B surface antigen, hemagglutinin, neuraminidase, influenza M protein, PfHRP2, pLDH, aldolase, MSP1, MSP2, AMA1, Der-p-1, Der-f-1, adipogenesis-associated protein, AFP, AIM-2, ART-4, BAGE, alpha-fetoprotein, BCL-2, Bcr-Abl, BING-4, CEA, CPSF, CT, cyclin DIEp-CAM, EphA2, EphA3, and E LF-2, FGF-5, G250, Gonadotropin-releasing hormone, HER-2, Intestinal carboxylesterase (iCE), IL13Rα2, MAGE-1, MAGE-2, MAGE-3, MART-1, MART-2, M-CSF, MDM-2, MMP-2, MUC-1, NY-EOS-1, MUM-1, MUM-2, MUM-3, p53, PBF, PRAME, PSA, PSMA, RAGE-1, RNF43, RU1, RU2AS, SART-1, SART-2, SART-3, SAGE-1, SCRN 1, SOX2, SOXIO, STEAP1, survivin (BIRC5), Telomerase, TGFβR1 Antigens such as 1, TRAG-3, TRP-1, TRP-2, TERT, or WT1; viruses derived from, such as vaccinia virus, vaccinia virus, pseudovaccinia virus, human herpesvirus 1, human herpesvirus 2, cytomegalovirus, human adenovirus AF, polyomavirus, human papillomavirus, parvovirus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, orthoreovirus, rotavirus, Ebola virus, parainfluenza virus, influenza virus (e.g., influenza A virus, influenza B virus, influenza C virus), measles. Antigens of herpesviruses, mumps virus, rubella virus, pneumovirus, human respiratory syncytial virus, rabies virus, California encephalitis virus, Japanese encephalitis virus, Hantavirus, lymphocytic choriomeningitis virus, coronaviruses (e.g., MERS-CoV, SARS-CoV-1, SARS-CoV-2, OC43, HKU1, bat coronavirus, other beta coronaviruses), enteroviruses, rhinoviruses, polioviruses, noroviruses, flaviviruses, dengue virus, West Nile virus, yellow fever virus, and varicella virus;Derived from bacteria such as Bacillus anthracis, Brucella, Bordetella pertussis, Candida, Chlamydia pneumoniae, Chlamydia psittaci, Cholera, Clostridium botulinum, Coccidioides immitis, Cryptococcus, Diphtheria, Escherichia coli O151:H7, Enterohemorrhagic Escherichia coli, Enterotoxigenic Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Legionella, Leptospira, Listeria, Neisseria meningitidis, and Mycoplasma pneumoniae. Antigens of mycobacteria, pertussis, pneumonia, Salmonella, Shigella, Staphylococcus, Streptococcus pneumoniae, and Yersinia enterocolitis; or antigens derived from protozoa such as Plasmodium (Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, or Plasmodium knowlesi).

[0361] The antigen may be, but is not limited to, allergens derived from cells, cell extracts, proteins, polypeptides, peptides, peptide mimics of polysaccharides, and other molecules such as small molecules, lipids, glycolipids, plant, animal, fungal, insect, food, drug, dust, and mite carbohydrates. Allergens include, but are not limited to, ambient air allergens; plant pollen (e.g., ragweed / hay fever); weed pollen allergens; grass pollen allergens; Johnson's grass; tree pollen allergens; ryegrass; arachnid allergens (e.g., house dust mite allergens); storage mite allergens; Japanese cedar pollen / hay fever; mold / fungal spore allergens; animal allergens (e.g., allergens in dogs, guinea pigs, hamsters, gerbils, rats, mice, etc.); food allergens (e.g., crustaceans, nuts, citrus fruits, flour, coffee); insect allergens (e.g., fleas, cockroaches); venom (Hymenoptera, wasps, bees, hornets, bumblebees, fire ants); bacterial allergens (e.g., streptococcal antigens); parasite allergens (e.g., roundworm antigens); viral antigens; drug allergens; hormones (e.g., insulin); enzymes (e.g., streptokinase); and drugs or chemicals that can act as incomplete antigens or haptens (e.g., acid anhydrides and isocyanates). When a hapten is used in the compositions of this disclosure, it may attach to a carrier to form a hapten-carrier adduct. The hapten-carrier adduct is capable of eliciting a humoral immune response, while the hapten itself does not induce antibody production. Non-limiting examples of haptens are aniline, urushiol (a toxin found in poison ivy), hydralazine, fluorescein, biotin, digoxin, and dinitrophenol.

[0362] In some embodiments, the antigen is derived from, for example, a family of microribonucleoviridae (… Picornaviride ), Caliciviridae ( Calciviridae ), Astroviridae ( Astroviridae ), Clothviridae ( Togaviridae Flaviviridae ( Flaviviridae Coronavirus family ( Coronaviridae Arteritis Virology Department ( Arteriviridae ), Rhabdoviridae ( Rhabndoviridae Filoviridae ( Filoviridae ), Paramyxoviridae ( Paramyxoviridae ), Bonaviridae ( Bornaviridae Orthomyxoviridae ( Orthomyxoviridae Bunyaviridae ( Bunyaviridae ), Arenaviridae ( Arenaviridae ), Reoviridae ( Reoviridae Retroviridae ( Retroviridae ), Polyomaviridae ( Polyomaviridae Herpesviridae ( Herpesviridae ), Poxviridae ( Poxviridae ), Papillomavirus Family ( Papillomaviridae ),Pepadnaviridae Adenoviridae ( Adenoviridae Parvoviridae ( Parvoviridae Hepatitis E Virology ( ) Hepeviridae ), Porconiidae ( Circoviridae ( ) viruses or combinations thereof, but not limited to them.

[0363] In some embodiments, the antigen is derived from, for example, Bacillus genus ( Bacillus Bordetella spp. Bordetella ), genus *Borrelia* Borrelia Brucella ( ) Brucella ), Campylobacter spp. Campylobacter Chlamydia ( ) Chlamydia Clostridium ( Clostridium Corynebacterium spp. Corynebacterium ), Enterococcus ( Enterococcus Escherichia coli spp. Escherichia Haemophilus spp. Haemophilus ), Helicobacter spp. Helicobacter Legionella ( ) Legionella Leptospira ( ) Leptospira Listeria ( ) Listeria ), Mycobacterium ( Mycobacterium Mycoplasma genus Mycoplasma ), Neisseria spp. Neisseria ), Pseudomonas spp. Pseudomonas ), Rickettsia species ( Rickettsia Salmonella ( Salmonella ), Shigella spp. Shigella Staphylococcus spp. Staphylococcus Streptococcus ( Streptococcus ), Vibrio genus ( Vibrio Yersinia spp. Yersinia (bacteria or combinations thereof, but not limited to)

[0364] In other embodiments, the antigen is a disease-associated antigen, in which it is desirable to isolate the antigen in circulation, such as amyloid protein (e.g., Alzheimer's disease).

[0365] In some implementations, the nucleic acid regulates or modulates cell function.

[0366] The term "cellular function" as used in this article refers to various cellular or biological processes, such as, but not limited to, biosynthesis, cell division, cell cycle regulation, cell metabolism, ion transport, absorption, secretion, homeostasis, replication, transcription, translation, cell signaling, endocytosis, efflux, phagocytosis, apoptosis, DNA replication, DNA repair, protein synthesis, gene regulation, cell repair, cell growth, cell differentiation, cell transport, cell proliferation, metabolic pathways, etc.

[0367] The terms “regulation” or “modulation” are used interchangeably in this article and refer to the act of controlling or exerting a modifying or controlling effect on cellular or biological processes.

[0368] Messenger RNA (mRNA)

[0369] Messenger RNA (mRNA) is a polymer of ribonucleotides encoding at least one protein, polypeptide, or peptide. Typically, mRNA includes at least a coding region, a 5' UTR, a 3' UTR, a 5' cap, and a poly(A) tail. The UTR (untranslated region) is located flanking the coding region or open reading frame (ORF). The 5' UTR and 3' UTR are the mRNA segments preceding the start codon and following the stop codon, respectively. The 5' UTR has a cap composed of altered nucleotides (5' cap). At its 3' end, mRNA also contains a polyadenylated region with adenine nucleotides, known as the poly(A) tail.

[0370] In some embodiments, the mRNA may be unmodified, modified, or a combination of both. The modification may be in the nucleobases of the nucleotide, the sugar moiety of the nucleotide, or the phosphate group of the nucleotide. In some embodiments, the unmodified mRNA may contain naturally occurring nucleosides such as adenosine, guanosine, cytidine, and uridine. The mRNA may contain one or more modified nucleosides, such as adenosine analogs, guanosine analogs, cytidine analogs, uridine analogs, or combinations thereof.

[0371] In some embodiments, the one or more modified nucleosides are nucleoside analogs selected from 2-aminoadenosine, 3-methyladenosine, 7-deadenosine, 7-deadenosine, 8-oxoadenosine, 8-oxoguanosine, or combinations thereof.

[0372] In some embodiments, the one or more modified nucleosides are uridine analogs selected from propynyl-uridine, pseudouridine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine, 3-methyl-uridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 2-thio-2'-O-methyl-uridine, 5-methoxycarbonylmethyl-2'-O-methyl-uridine, 5-carboxymethylaminomethyl-2'-O-methyl-uridine, 3,2'- O-dimethyluridine, 5-propynyluridine, 1-propynyl-pseudouridine, 5-tauronicomethyluridine, 1-tauronicomethyl-pseudouridine, 5-tauronicomethyl-2-thio-uridine, 1-tauronico-4-thio-pseudouridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-denitro-pseudouridine, 2-thio-1-methyl-1-denitro-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydro-pseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine or 4-methoxy-2-thio-pseudouridine or combinations thereof.

[0373] In some embodiments, the one or more modified nucleosides are cytidine analogs selected from 5-methylcytidine, C5-propynyl-cytidine, C5-methylcytidine, pseudocytidine, 1-methyl-pseudocytidine, pyrrolo-pseudocytidine, 4-thio-pseudocytidine, 4-thio-1-methyl-pseudocytidine, 4-thio-1-methyl-1-denitro-pseudocytidine, 1-methyl-1-denitro-pseudocytidine, 4-methoxy-1-methyl-pseudocytidine, or combinations thereof.

[0374] Methods for preparing modified nucleosides are well known in the art.

[0375] In some embodiments, the modified nucleoside is a pseudouridine, such as 1-methyl-pseudouridine, 1-propynyl-pseudouridine, 1-carboxymethyl-pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 4-methoxy-pseudouridine, or 4-methoxy-2-thio-pseudouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, dihydro-pseudouridine, or combinations thereof.

[0376] In some implementations, mRNA is obtained from natural sources (i.e., isolated from cells), produced using a recombinant expression system, or chemically synthesized.

[0377] The mRNA disclosed herein can be synthesized via in vitro transcription (IVT). In brief, IVT typically uses a DNA template containing a promoter, a ribonucleotide triphosphate conjugate, a buffer system that may include DTT and magnesium ions, and a suitable RNA polymerase (e.g., T3, T7, or SP6 RNA polymerase), DNase I, pyrophosphatase, and / or RNase inhibitors. Specific conditions may vary depending on the application. Methods for preparing mRNA via IVT reactions are well known in the art (see, for example, Beckert, Bertrand and Masquida, Benoit, Methods in Molecular Biology (2011) 703, 29-41; Brunelle, Julie L. and Green Rachel, Methods in Enzymology (2013) 530, 101-114; Kamakaka, Rohinton T. and Kraus W. Lee, Current Protocols in Cell Biology (1999) 11.6.1-11.6.17; Kanwal, Fariha et al., Cellular Physiology and Biochemistry (2018) 48:1915-1927; WO2018157153; WO2020185811; WO2022082001).

[0378] In some embodiments, the in vitro transcription is performed in a single batch. In some embodiments, the IVT reaction includes capping and tailing reactions performed either co-transcriptionally or separately. A cap analogue is added to the in vitro transcription reaction and incorporated into the 5' end of the mRNA during the reaction. Alternatives to capping include adding the cap structure post-transcriptionally via an enzymatic reaction. The poly(A) tail can be incorporated into the DNA template sequence, so the poly(A) tail is incorporated into the mRNA via T7 RNA polymerase during in vitro transcription. Alternatives to tailing include adding the poly(A) tail post-transcriptionally via an enzymatic reaction. In some embodiments, the capping and tailing reactions are performed co-transcriptionally, i.e., during the IVT reaction. In some embodiments, the capping and tailing reactions are performed separately from the IVT reaction.

[0379] The mRNA produced as a result of the IVT reaction can be purified using techniques known in the art, such as centrifugation, filtration, and / or chromatography. Purification of the mRNA can be performed before or after the capping and tailing steps. The synthesized mRNA can be purified by ethanol precipitation, filtration, or chromatography. In some embodiments, tangential flow filtration is used to purify the mRNA. In some embodiments, a chromatographic step is used to purify the mRNA. In other embodiments, a combination of filtration and chromatographic steps is used to purify the mRNA.

[0380] In some embodiments, the suitable mRNA sequence is an mRNA sequence encoding a protein, peptide, polypeptide, or antibody. In some embodiments, the suitable mRNA sequence is codon-optimized for efficient expression in a host cell or organism. Codon optimization typically involves modifying the naturally occurring or wild-type nucleic acid sequence encoding the peptide, polypeptide, or protein to achieve the highest possible expression of the peptide, polypeptide, protein, or antibody without altering the amino acid sequence.

[0381] mRNA of any length can be encapsulated or formulated in the lipid nanoparticles of this disclosure. The length of the mRNA used in the lipid nanoparticles of this disclosure depends on the gene product or protein or protein fragment to be incorporated into the lipid nanoparticles. Therefore, the length of the mRNA can be very short, extending to about a few hundred nucleotides, or very long, extending to several thousand nucleotides. In some implementations, the mRNA length is about 0.5 kb, about 1 kb, about 1.5 kb, about 2 kb, about 2.5 kb, about 3 kb, about 3.5 kb, about 4 kb, about 4.5 kb, about 5 kb, about 5.5 kb, about 6 kb, about 6.5 kb, about 7 kb, about 7.5 kb, about 8 kb, about 8.5 kb, about 9 kb, about 9.5 kb, about 10 kb, about 11 kb, about 12 kb, about 13 kb, about 14 kb, about 15 kb, about 16 kb, about 17 kb, about 18 kb, about 19 kb, about 20 kb, about 22 kb, about 24 kb, about 26 kb, about 28 kb, or about 30 kb. In other embodiments, the length of the mRNA is about 0.5 to 30 kb, about 0.5 to 25 kb, or about 0.5 to 20 kb. In other embodiments, the length of the mRNA is about 1 to 20 kb, about 1 to 15 kb, about 1 to 10 kb, about 1 to 9 kb, about 1 to 8 kb, about 1 to 7 kb, about 1 to 6 kb, about 1 to 5 kb, about 1 to 4 kb, about 1 to 3 kb, or about 1 to 2 kb.

[0382] In some embodiments, the mRNA is circular. In other embodiments, the mRNA is linear.

[0383] In some embodiments, the mRNA is self-amplifying or self-replicating. As used herein, self-amplifying or self-replicating mRNA means mRNA that replicates itself after delivery to a cell. Such mRNAs typically contain a replicase, usually derived from alphaviruses, which is capable of amplifying the original mRNA strand encoding the protein of interest after delivery to the cell.

[0384] The mRNA present in the lipid nanoparticle composition may be present in a bioeffective or therapeutically effective amount. In some embodiments, the bioavailable amount of mRNA present in the lipid nanoparticle composition is in the range of 0.1 μg to 1000 μg, 0.1 μg to 950 μg, 0.1 μg to 900 μg, 0.1 μg to 850 μg, 0.1 μg to 800 μg, 0.1 μg to 750 μg, 0.1 μg to 700 μg, 0.1 μg to 650 μg, 0.1 μg to 600 μg, 0.1 μg to 550 μg, 0.1 μg to 500 μg, 0.1 μg to 450 μg, 0.1 μg to 400 μg, 0.1 μg to 350 μg, 0.1 μg to 300 μg, 0.1 μg to 250 μg, 0.1 μg to 200 μg, 0.1 μg to 150 μg, 0.1 μg to 100 μg. The amounts are in the range of 0.1 μg to 75 μg, 0.1 μg to 50 μg, 0.1 μg to 25 μg, 0.1 μg to 20 μg, 0.1 μg to 15 μg, 0.1 μg to 10 μg, 0.1 μg to 5 μg, or any range thereof. In some embodiments, the bioavailable amount of mRNA present in the lipid nanoparticle composition is about 0.1 μg to 1000 μg, 0.1 μg to 950 μg, 0.1 μg to 900 μg, 0.1 μg to 850 μg, 0.1 μg to 800 μg, 0.1 μg to 750 μg, 0.1 μg to 700 μg, 0.1 μg to 650 μg, 0.1 μg to 600 μg, 0.1 μg to 550 μg, 0.1 μg to 500 μg, or any range thereof.

[0385] In some embodiments, the bioavailable amount of mRNA present in the lipid nanoparticle composition is 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 0.6 μg, 0.7 μg, 0.8 μg, 0.9 μg, 1 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg. μg, 180 μg, 190 μg, 200 μg, 220 μg, 240 μg, 260 μg, 280 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg, 1000 μg or any part or fraction thereof.

[0386] In some embodiments, the mRNA encodes one or more proteins, one or more antibodies, or a combination thereof. The mRNA encoding one or more proteins or one or more antibodies can belong to any organism, such as prokaryotes or eukaryotes, single-celled organisms, multicellular organisms, viruses, bacteria, mycoplasma, protozoa, animals, or humans.

[0387] Non-coding RNA (ncRNA)

[0388] The terms "non-coding RNA" or "ncRNA" are used interchangeably to refer to any RNA molecule that is not normally translated into peptides or proteins, but can sometimes be translated into them. This includes long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). The term ncRNA also includes such RNAs that encode small peptides, such as lncRNA.

[0389] In some embodiments, the nucleic acid component of the lipid nanoparticle composition comprises ncRNA. The ncRNA may be naturally occurring or wild-type. In other embodiments, the ncRNA may be synthetically produced.

[0390] In some implementations, the ncRNA is single-stranded or double-stranded.

[0391] In some implementations, the ncRNA can be a few nucleotides long or a few thousand nucleotides long.

[0392] In some embodiments, the ncRNA includes long noncoding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), or combinations thereof.

[0393] In some embodiments, the long non-coding RNA (lncRNA) is longer than 200 nucleotides.

[0394] deoxyribonucleic acid (DNA)

[0395] Any DNA molecule capable of transferring genes into cells to express transcripts, for example, can be incorporated into the lipid nanoparticle compositions described herein.

[0396] The terms “DNA sequence” or “DNA segment” or “gene” are used interchangeably to refer to a DNA segment or sequence that can be used to produce transcripts, which can be messenger RNA (mRNA) or non-coding RNA (ncRNA), such as long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), and PIWI-interacting RNA (piRNA), transfer RNA (tRNA), or ribosomal RNA (rRNA).

[0397] In some embodiments, the DNA molecule is obtained from a natural source. In other embodiments, the DNA molecule is produced through recombination or synthesis.

[0398] In some embodiments, the DNA molecule is modified or unmodified, linear or circular.

[0399] In some embodiments, the DNA molecule is double-stranded or single-stranded.

[0400] In some embodiments, the DNA molecule includes a coding sequence or a non-coding sequence.

[0401] In some implementations, the DNA molecule is a few nucleotides long to several thousand nucleotides long.

[0402] Treatment

[0403] This document discloses methods for treating or preventing diseases. These methods may include administering to a subject in need a lipid nanoparticle composition comprising a cationic lipid represented by formula (I) or formula (II) disclosed herein. The disease may be cancer, an infectious disease, or a disease and / or disorder that is improved by humoral and / or cellular immune responses.

[0404] The term "infectious disease" refers to a disorder caused by organisms such as bacteria, viruses, fungi, protozoa, worms, mycoplasma, parasites, or combinations thereof. Non-limiting examples of infectious diseases include those caused by organisms from the family Picornaviridae (Piacolviridae). Picornaviride ), Caliciviridae ( Calciviridae ), Astroviridae ( Astroviridae ), Clothviridae ( Togaviridae Flaviviridae ( Flaviviridae Coronavirus family ( Coronaviridae Arteritis Virology Department ( Arteriviridae ), Rhabdoviridae ( Rhabndoviridae Filoviridae ( Filoviridae ), Paramyxoviridae ( Paramyxoviridae ), Bonaviridae ( Bornaviridae Orthomyxoviridae ( Orthomyxoviridae Bunyaviridae ( Bunyaviridae ), Arenaviridae ( Arenaviridae ), Reoviridae ( Reoviridae Retroviridae ( Retroviridae ), Polyomaviridae ( Polyomaviridae Herpesviridae ( Herpesviridae ), Poxviridae ( Poxviridae ), Papillomavirus Family ( Papillomaviridae ), Pepadnaviridae Adenoviridae ( Adenoviridae Parvoviridae ( Parvoviridae Hepatitis E Virology ( ) Hepeviridae ), Porconiidae ( Circoviridae Infectious diseases caused by viruses of the genus Bacillus ( ); Bacillus Bordetella spp. Bordetella ), genus *Borrelia* Borrelia Brucella ( ) Brucella ), Campylobacter spp. Campylobacter Chlamydia ( ) Chlamydia Clostridium ( Clostridium Corynebacterium spp. Corynebacterium ), Enterococcus ( Enterococcus Escherichia coli spp. Escherichia Haemophilus spp. Haemophilus ), Helicobacter spp. Helicobacter Legionella ( ) LegionellaLeptospira ( ) Leptospira Listeria ( ) Listeria ), Mycobacterium ( Mycobacterium Mycoplasma genus Mycoplasma ), Neisseria spp. Neisseria ), Pseudomonas spp. Pseudomonas ), Rickettsia species ( Rickettsia Salmonella ( Salmonella ), Shigella spp. Shigella Staphylococcus spp. Staphylococcus Streptococcus ( Streptococcus ), Vibrio genus ( Vibrio Yersinia spp. Yersinia Infectious diseases caused by bacteria of the genus Plasmodium; caused by Plasmodium ( Plasmodium Trypanosoma genus ( Trypanosoma Leishmania ( ) Leishmania ), Toxoplasma ( Toxoplasma ), genus Entamoeba ( Entamoeba ), Trichomonas genus ( Trichomonas Infectious diseases caused by protozoa, or combinations thereof.

[0405] As used herein, the terms “cancer,” “cancer cell,” “tumor,” and “tumor cell” (which may be used interchangeably) refer to cells exhibiting abnormal growth characterized by a significant loss of control over cell proliferation, or cells that have become immortalized. The terms “cancer” or “tumor” include metastatic and non-metastatic cancers or tumors. Cancer can be diagnosed using standards generally accepted in the art, including the presence of malignancy.

[0406] The "humoral immune response" referred to in this article encompasses antibody production and its accompanying auxiliary processes, such as activation of type 2 helper T cells (Th2) and cytokine production, allotype switching, affinity maturation, and memory cell activation. It also refers to the effector functions of antibodies, such as toxin neutralization, classical complement activation, promotion of phagocytosis, and pathogen elimination. Since the humoral immune response is aided by CD4+ Th2 cells, the activation or production of this cell type also indicates the humoral immune response as defined in this article.

[0407] The term "humoral immune response" as used herein may also encompass the generation and / or activation of T helper cells. Helper T cells are a subset of helper effector T lymphocytes characterized by the secretion of host defense cytokines such as interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), IL-17, IL-17F, IL-21, and IL-22. Helper T cells are thought to contribute to humoral immune responses, playing a crucial role in antimicrobial immunity and infection prevention. Their IL-22 production is believed to stimulate epithelial cells to produce antimicrobial proteins, and IL-17 production may be involved in the recruitment, activation, and migration of neutrophils to protect the host from infection by various bacterial and fungal species.

[0408] In some embodiments, the antigen encoded by nucleic acid in the compositions of this disclosure may be a cancer or tumor-associated protein, such as a membrane-bound cancer antigen that can be recognized by an antibody.

[0409] Cancers that can be treated and / or prevented by using or applying the compositions of this disclosure include, but are not limited to, carcinoma, adenocarcinoma, lymphoma, leukemia, sarcoma, blastoma, myeloma, and germ cell tumors. In one embodiment, the cancer may be caused by a pathogen such as a virus. Viruses associated with cancer development are known to those skilled in the art and include, but are not limited to, human papillomavirus (HPV), John Cunningham virus (JCV), human herpesvirus 8, Epstein-Barr virus (EBV), Merkel cell polyomavirus, hepatitis C virus, and human T-cell leukemia virus-1. The compositions of this disclosure can be used to treat or prevent cancer, such as reducing the severity of cancer or preventing cancer recurrence. Cancers that may benefit from the compositions of this disclosure include any malignant cells expressing one or more tumor-specific antigens.

[0410] In some embodiments, the antigen may be a toxin or allergen that can be neutralized by antibodies.

[0411] In some embodiments, the antigen may be a disease-associated antigen, where it is desirable to isolate the antigen in circulation, such as amyloid protein (e.g., Alzheimer's disease). Therefore, the compositions of this disclosure may be suitable for treating and / or preventing neurodegenerative diseases in subjects in need, wherein the neurodegenerative disease is associated with antigen expression. The subject may have a neurodegenerative disease or may be at risk of developing a neurodegenerative disease. Neurodegenerative diseases that can be treated and / or prevented by using or administering the compositions of this disclosure include, but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). For example, Alzheimer's disease is characterized by the binding of β-amyloid plaques and / or tau protein in the brains of patients with Alzheimer's disease (see, for example, Goedert and Spillantini, Science, 314: 777-781, 2006). Herpes simplex virus type 1 is also believed to play a pathogenic role in people carrying a susceptible version of the apoE gene (Itzhaki and Wozniak, J Alzheimers Dis 13: 393-405, 2008).

[0412] In some embodiments, the composition may comprise a mixture of B-cell epitopes as an antigen for inducing a humoral immune response. The B-cell epitopes may be linked to form a single polypeptide.

[0413] In some embodiments, the antigen may be any peptide or polypeptide capable of inducing a specific humoral immune response against a specific conformation on target tumor cells.

[0414] In some embodiments, the compositions disclosed herein can be used to induce humoral and / or cellular immune responses in a subject. Therefore, the compositions described herein can be used to treat or prevent diseases and / or disorders that are improved by humoral immune responses, such as those involving B cell and antibody production. The compositions can be applied to any situation requiring the administration of an antigen to a subject to induce a humoral immune response or antibody production.

[0415] In contrast to cell-mediated immunity, humoral immune responses are mediated by secretory antibodies produced in cells of the B lymphocyte lineage (B cells). These secretory antibodies bind to antigens on the surface of antigens, such as foreign substances and / or pathogens (e.g., viruses, bacteria, etc.), and label them for destruction.

[0416] Antibodies are antigen-specific glycoprotein products of a subset of leukocytes called B lymphocytes (B cells). The binding of an antigen to an antibody expressed on the surface of a B cell can induce an antibody response, including stimulating the B cell to become activated, undergo mitosis, and terminally differentiate into plasma cells, which are specialized for synthesizing and secreting antigen-specific antibodies.

[0417] B cells are the sole producers of antibodies during the immune response, making them a key element of effective humoral immunity. In addition to producing large quantities of antibodies, B cells also act as antigen-presenting cells, delivering antigens to T cells such as helper T CD4 cells or cytotoxic CD8 cells, thereby propagating the immune response. B cells and T cells are part of the adaptive immune response and are crucial for vaccine efficacy. During an active immune response induced by vaccination or natural infection, antigen-specific B cells are activated and cloned. During this expansion, B cells evolve to have a higher affinity for epitopes. B cell proliferation can be indirectly induced by activated helper T cells or directly induced by stimulating receptors such as Toll-like receptors (TLRs).

[0418] Antigen-presenting cells, such as dendritic cells, macrophages, and B cells, are attracted to the vaccination site and can interact with the antigens and adjuvants contained in the vaccine. The adjuvants stimulate the cells to become activated, and the antigens provide a blueprint for the target. Different types of adjuvants deliver different stimulatory signals to the cells. For example, polyI:C (a TLR3 agonist) can activate dendritic cells but not B cells. Adjuvants such as Pam3Cys, Pam2Cys, and FSL-1 are particularly adept at activating and initiating B cell proliferation, which is expected to promote antibody responses (Moyle et al., Curr Med Chem, 2008; So., J Immunol, 2012, the entirety of which is incorporated herein by reference).

[0419] The compositions disclosed herein may be able to protect subjects from diseases, disorders, or discomforts associated with antigens that can induce humoral immune responses by stimulating a strong antibody response.

[0420] This includes, but is not limited to, infectious diseases, cancers involving cancer antigens that bind to membrane surfaces recognized by antibodies, diseases where it is desirable to isolate antigens (such as amyloid) in circulation (such as Alzheimer's disease), neutralizing toxins with antibodies, and treating allergies by neutralizing viruses or bacteria or neutralizing allergens (such as pollen) with antibodies.

[0421] In some embodiments, the composition can be administered orally, nasally, rectally, or parenterally. Parenterally administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and local administration. In some embodiments, the composition is administered via intramuscular, subcutaneous, or intradermal injection.

[0422] The amount of composition used in a single treatment may vary due to a variety of factors, such as the nature of the negatively charged molecules to be delivered, the type of formulation, and the body type of the subject. Those skilled in the art will be able to determine the effective amount of composition to be used in a particular application without conducting extensive experiments.

[0423] Professional technicians can determine the appropriate treatment regimen, route of administration, dosage, etc., for any specific application to achieve the desired results. Factors that can be considered include, for example, the nature of the peptide to be expressed, the disease state to be prevented or treated, the subject's age, physical condition, weight, sex, and diet, as well as other clinical factors.

[0424] The subject to be treated can be any vertebrate, preferably a mammal, and more preferably a human.

[0425] Implementation

[0426] Some embodiments of this disclosure are described in the numbered paragraphs below.

[0427] 1. A cationic lipid represented by formula (I) or an isomer or salt thereof:

[0428] Formula (I), in: R1 and R2 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L7-R5 and -NR6R7; R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L6, and L7 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N, provided that when A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or S, one of R1 or R2 does not exist; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0429] 2. A cationic lipid represented by formula (II) or an isomer or salt thereof:

[0430] Equation (II), in: R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3)y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; (R 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L7, and L8 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Z is -CH2-, O, N, or S; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

[0431] 3. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently H or -OH.

[0432] 4. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently C 1-10 alkyl.

[0433] 5. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently C 2-10 Alkenyl group.

[0434] 6. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently C 2-10 Alkyne group.

[0435] 7. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently saturated or unsaturated C. 3-10 Cycloalkyl.

[0436] 8. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently a saturated or unsaturated C-type lipid containing 1-4 heteroatoms. 3-10 Heterocyclic alkyl groups.

[0437] 9. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently H or -O-L7-R5.

[0438] 10. The cationic lipid according to paragraph 1, wherein R1 is H and R2 is -O-L7-R5.

[0439] 11. The cationic lipid according to paragraph 1, wherein R1 is -O-L7-R5 and R2 is H.

[0440] 12. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently -O-L7-R5.

[0441] 13. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently H or -NR6R7.

[0442] 14. The cationic lipid according to paragraph 1, wherein R1 is H and R2 is -NR6R7.

[0443] 15. The cationic lipid according to paragraph 1, wherein R1 is -NR6R7 and R2 is H.

[0444] 16. The cationic lipid according to paragraph 1, wherein R1 and R2 are each independently -NR6R7.

[0445] 17. The cationic lipid according to paragraph 2, wherein Z is -CH2-, O, N or S.

[0446] 18. The cationic lipid according to paragraph 17, wherein Z is -CH2-.

[0447] 19. The cationic lipid according to paragraph 17, wherein Z is O.

[0448] 20. The cationic lipid according to paragraph 17, wherein Z is N.

[0449] 21. The cationic lipid according to paragraph 2 or any of paragraphs 17-20, wherein (R 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 The aryl groups are -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4.

[0450] 22. The cationic lipid according to paragraph 21, wherein (R) 10 ) q H is a variable where q is an integer in the range of 0 to 4.

[0451] 23. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is -OH, -CH2OH, or both, where q is an integer in the range of 0 to 4.

[0452] 24. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is C 1-10 Alkyl group, where q is an integer in the range of 0 to 4.

[0453] 25. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is C 2-10 Alkenyl, where q is an integer in the range of 0 to 4.

[0454] 26. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is C 2-10 Alkyne group, where q is an integer in the range of 0 to 4.

[0455] 27. The cationic lipid according to paragraph 21, wherein (R) 10 ) q Is it saturated or unsaturated C? 3-10 Cycloalkyl, where q is an integer in the range of 0 to 4.

[0456] 28. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is a saturated or unsaturated carbon containing 1-4 heteroatoms. 3-10 Heterocyclic alkyl groups, where q is an integer in the range of 0 to 4.

[0457] 29. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is -O-L8-R5, where q is an integer in the range of 0 to 4.

[0458] 30. The cationic lipid according to paragraph 21, wherein (R) 10 ) q It is -NR6R7, where q is an integer in the range of 0 to 4.

[0459] 31. The cationic lipid according to any of paragraphs 21-30, wherein q is an integer in the range of 0 to 3, 0 to 2, or 0 to 1.

[0460] 32. The cationic lipids according to any of paragraphs 1-2 or 9-12, wherein L7 is either absent or C 1-10 Alkylene, C 2-10 imide or C 2-10 Alynyl group.

[0461] 33. The cationic lipids according to paragraph 32, wherein L7 is absent.

[0462] 34. The cationic lipids according to paragraph 29, wherein L8 is either absent or C 1-10 Alkylene, C 2-10 imide or C2-10 Alynyl group.

[0463] 35. The cationic lipid according to paragraph 34, wherein L8 is absent.

[0464] 36. The cationic lipid according to any of paragraphs 9-12 or paragraph 29, wherein R5 is H, -OH, C 1-10 Alkyl, saturated or unsaturated C 3-10 Cycloalkyl groups, saturated or unsaturated C atoms containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0465] 37. The cationic lipid according to paragraph 36, wherein R5 is a C containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

[0466] 38. The cationic lipid according to paragraph 36, wherein R5 is a C containing 1-4 heteroatoms. 5-9 Mixed aromatic compounds.

[0467] 39. The cationic lipids according to any of paragraphs 13-16 and 30, wherein R6 and R7 are independently selected from H, -OH, C. 1-10 Alkyl, saturated or unsaturated C 3-10 Cycloalkyl groups, saturated or unsaturated C atoms containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0468] 40. The cationic lipid according to paragraph 39, wherein R6 and R7 are independently selected from H, -OH, C. 1-6 Alkyl groups and saturated or unsaturated C groups containing 1-4 heteroatoms 3-8 Heterocyclic alkyl groups.

[0469] 41. The cationic lipid according to any of the preceding paragraphs, wherein R3 and R4 are independently selected from branched or unbranched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

[0470] 42. The cationic lipid according to paragraph 41, wherein R3 and R4 are independently selected from C 1-20 Alkyl, C 2-20 alkenyl and C 2-20 Alkyne group.

[0471] 43. The cationic lipid according to paragraph 41, wherein R3 and R4 are independently selected from -(CH2). m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

[0472] 44. The cationic lipid according to paragraph 41 or paragraph 43, wherein m, n and y are each independently an integer in the range of 0 to 20, 0 to 16, 0 to 12, 0 to 10 or 0 to 8.

[0473] 45. The cationic lipid according to any of the preceding paragraphs, wherein L1 and L2 are independently selected from C 1-10 C 1-8 C 1-6 C 1-4 C 1-3 and C 1-2 Alkylene.

[0474] 46. ​​The cationic lipid according to any of the preceding paragraphs, wherein L1 and L2 are independently selected from C 2-10 C 2-8 C 2-6 and C 2-4 Alkenyl group.

[0475] 47. The cationic lipid according to any of the preceding paragraphs, wherein L3 and L4 are independently selected from C 1-10 C 1-8 C 1-6 C 1-4 C 1-3 and C 1-2 Alkylene.

[0476] 48. The cationic lipid according to any of the preceding paragraphs, wherein L3 and L4 are independently selected from C 2-10 C 2-8 C 2-6 and C 2-4 Alkenyl group.

[0477] 49. The cationic lipid according to any of the preceding paragraphs, wherein L5 is either absent or independently selected from C 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

[0478] 50. The cationic lipid according to any of the preceding paragraphs, wherein L6 is either absent or independently selected from C 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

[0479] 51. The cationic lipids described in any of paragraphs 49-50, wherein L5 and L6 are absent.

[0480] 52. The cationic lipid according to any of the preceding paragraphs, wherein X1 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

[0481] 53. The cationic lipid according to paragraph 52, wherein X1 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

[0482] 54. The cationic lipid according to any of the preceding paragraphs, wherein X2 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

[0483] 55. The cationic lipid according to paragraph 54, wherein X2 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

[0484] 56. A cationic lipid according to any of the preceding paragraphs, wherein A is H, a bond, or a saturated or unsaturated C. 3-10 cycloalkyl, C 6-10Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

[0485] 57. The cationic lipid according to paragraph 56, wherein A is a saturated or unsaturated C. 3-10 Cycloalkyl groups or saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups.

[0486] 58. The cationic lipid according to any of the preceding paragraphs, wherein A1 is -CH2- or N.

[0487] 59. The cationic lipid according to any of the preceding paragraphs, wherein the heteroatom is selected from O, N, S or P.

[0488] 60. The cationic lipid according to paragraph 59, wherein the heteroatom is selected from O, N or S.

[0489] 61. The cationic lipid according to any of the preceding paragraphs, wherein each alkyl, alkenyl, alkynylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group is independently and optionally substituted by one or more substituents.

[0490] 62. The cationic lipid according to paragraph 61, wherein the substituent is selected from H, -OH, Cl, Br, I, O, S, N, P, and optionally substituted C. 1-6 Alkoxy, optional substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 Alkyne group, optionally substituted saturated or unsaturated C 3-10 cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted saturated or unsaturated C-type compounds containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, optionally substituted C groups containing 1-4 heteroatoms 5-10 heteroaryl groups or combinations thereof.

[0491] 63. A lipid nanoparticle composition comprising a cationic lipid as described in any of paragraphs 1-62, and optionally additionally comprising phospholipids, sterols, PEG-lipids, or nucleic acids.

[0492] 64. A lipid nanoparticle composition comprising cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids as described in any of paragraphs 1-62.

[0493] 65. The lipid nanoparticle composition according to any one of paragraphs 63-64, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%.

[0494] 66. The lipid nanoparticle composition according to any one of paragraphs 63-64, wherein the phospholipid is present in an amount of 2 mol% to 65 mol%.

[0495] 67. The lipid nanoparticle composition according to any one of paragraphs 63-64, wherein the sterol is present in an amount of 20 mol% to 65 mol%.

[0496] 68. The lipid nanoparticle composition according to any one of paragraphs 63-64, wherein the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

[0497] 69. The lipid nanoparticle composition according to any one of paragraphs 63-68, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%, the phospholipid is present in an amount of 2 mol% to 65 mol%, the sterol is present in an amount of 20 mol% to 65 mol%, and the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

[0498] 70. The lipid nanoparticle composition according to any of paragraphs 63-69, further comprising an ionizable polymer.

[0499] 71. The lipid nanoparticle composition according to paragraph 70, wherein the ionizable polymer is present in an amount of 1 mol% to 25 mol%.

[0500] 72. The lipid nanoparticle composition according to any of paragraphs 63-71, wherein the nucleic acid is DNA, RNA, or a combination thereof.

[0501] 73. The lipid nanoparticle composition according to paragraph 72, wherein the RNA is mRNA, long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), or a combination thereof.

[0502] 74. The lipid nanoparticle composition according to paragraph 73, wherein the RNA is mRNA.

[0503] 75. The lipid nanoparticle composition according to paragraph 74, wherein the mRNA encodes one or more proteins, one or more antibodies, or a combination thereof.

[0504] 76. The lipid nanoparticle composition according to paragraph 74, wherein the mRNA encodes an antigen derived from a prokaryote or eukaryote, a single-celled organism, a multicellular organism, a virus, bacteria, mycoplasma, a protozoan, an animal, or a human.

[0505] 77. A method for delivering nucleic acids, the method comprising administering a lipid nanoparticle composition comprising a cationic lipid, phospholipid, sterol, PEG-lipid, and nucleic acid as described in any of paragraphs 1-62.

[0506] 78. A method of treating or preventing a disease, the method comprising administering a lipid nanoparticle composition to a subject in need, the composition comprising cationic lipids as described in any of paragraphs 1-62, and optionally additionally comprising phospholipids, sterols, PEG-lipids, or nucleic acids.

[0507] 79. A method for treating or preventing a disease, the method comprising administering a lipid nanoparticle composition to a subject in need, the composition comprising cationic lipids, phospholipids, sterols, PEG-lipids, and nucleic acids as described in any of paragraphs 1-62.

[0508] 80. The method according to any of paragraphs 78-79, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%.

[0509] 81. The method according to any of paragraphs 78-79, wherein the phospholipid is present in an amount of 2 mol% to 65 mol%.

[0510] 82. The method according to any of paragraphs 78-79, wherein the sterol is present in an amount of 20 mol% to 65 mol%.

[0511] 83. The method according to any of paragraphs 78-79, wherein the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

[0512] 84. The method according to any of paragraphs 78-83, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%, the phospholipid is present in an amount of 2 mol% to 65 mol%, the sterol is present in an amount of 20 mol% to 65 mol%, and the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

[0513] 85. The method described in any of paragraphs 78-84, further comprising an ionizable polymer.

[0514] 86. The method according to paragraph 85, wherein the ionizable polymer is present in an amount of 1 mol% to 25 mol%.

[0515] 87. The method described in any of paragraphs 78-86, wherein the nucleic acid is DNA, RNA, or a combination thereof.

[0516] 88. The method according to paragraph 87, wherein the RNA is mRNA, long noncoding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), or a combination thereof.

[0517] 89. The method described in paragraph 88, wherein the RNA is mRNA.

[0518] 90. The method according to paragraph 89, wherein the mRNA encodes one or more proteins, one or more antibodies, or a combination thereof.

[0519] 91. The method according to paragraph 89, wherein the mRNA encodes an antigen derived from a prokaryote or eukaryote, a single-celled organism, a multicellular organism, a virus, bacteria, mycoplasma, a protozoan, an animal, or a human.

[0520] 92. Use of the lipid nanoparticle composition according to any of paragraphs 63-76 in the preparation of a medicament for treating or preventing disease in a subject.

[0521] This disclosure is further illustrated by the following non-limiting embodiments. It should be understood that the embodiments are provided to illustrate this disclosure. Based on this description and exemplary implementations and embodiments, those skilled in the art can make various modifications or adaptations to this disclosure. Such modifications or adaptations are considered to be within the spirit and scope of this disclosure.

[0522] Example

[0523] The reactions described herein are generally carried out under inert conditions such as an N2 atmosphere, except for reactions involving moisture, water, or acids.

[0524] Example 1: Synthesis of 8,8'-((4-(((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azinediyl)dioctanoic acid di(heptadecan-9-yl) ester (PVXL-202)

[0525] Step 1: Synthesis of heptadecano-9-yl 8-bromooctanoate (3)

[0526] DCC (13.87 g, 67.23 mmol) and DMAP (1.64 g, 13.446 mmol) were added to an ice-cold solution of 8-bromooctanoic acid (1) (10 g, 44.82 mmol) in DCM (150 mL) with stirring. The reaction mixture was stirred under ice-cold conditions for 30 min. After 30 min, heptadecano-9-ol (2) (11.49 g, 44.82 mmol) was added to the reaction mixture, and the reaction mixture was allowed to reach room temperature and stirred for 6 h. After 6 h, the reaction mixture was filtered through a diatomaceous earth pad and washed with DCM (2 x 100 mL). The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by combiflash chromatography using 5% EtOAc in heptane as the eluent to give heptadecano-9-ol ester of 8-bromooctanoic acid (3) (15 g, 72%) as a colorless liquid.

[0527] Step 2: Synthesis of 8,8'-((4-hydroxybutyl)azonyl)dioctanoic acid di(heptadecan-9-yl) ester (5)

[0528] At room temperature, K₂CO₃ (930 mg, 6.73 mmol) and Cs₂CO₃ (722 mg, 2.24 mmol) were added to a stirred solution of 4-aminobut-1-ol (4) (200 mg, 2.24 mmol) in ACN (10.0 mL) and THF (10.0 mL), and the mixture was stirred for 1 h. After 1 h, heptadecano-9-yl 8-bromooctanoate (3) (2.18 g, 4.71 mmol) and KI (372 mg, 2.24 mmol) were added to the reaction mixture, and the mixture was stirred at 80 °C for 9 h. After 9 h, the reaction mixture was quenched with ice-cooled water (20 mL), stirred for 10 min, and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (20 mL), dehydrated on Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by combiflash chromatography using 40-50% EtOAc in heptane as the eluent to give 8,8'-((4-hydroxybutyl)azanidinediyl)dioctanoic acid di(heptadecano-9-yl) ester (5) (1.5 g, 78%) as a colorless liquid.

[0529] Step 3: Synthesis of 8,8'-((4-(((2R,3R,4R,5R)-3,4-diacetoxy-5-(acetoxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azinediyl)dioctanoic acid di(heptadecano-9-yl) ester (7)

[0530] BF3·Et2O (0.12 mL, 0.94 mmol) was added to an ice-cold solution of triacetic acid (2S,3R,4R,5R)-5-(acetoxymethyl)tetrahydrofuran-2,3,4-triyl ester (6) (100 mg, 0.31 mmol) and 8,8'-((4-hydroxybutyl)azanidinediyl)dioctanoate di(heptadecano-9-yl) ester (5) (348 mg, 0.41 mmol) in a stirred solution of DCM (3.0 mL). The reaction mixture was then allowed to reach room temperature and stirred for 2 h. After 2 h, the reaction mixture was quenched with ice-cold water (20 mL), stirred for 10 min, and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with saturated NaHCO3 (20 mL) and brine (20 mL), dehydrated on Na2SO4, filtered, and concentrated under reduced pressure to obtain crude product. It was purified by combiflash chromatography using 0-50% EtOAc in heptane as eluent to obtain 8,8'-((4-(((2R,3R,4R,5R)-3,4-diacetoxy-5-(acetoxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azanediyl)dioctanoic acid di(heptadecano-9-yl) ester (7) (300 mg, crude product) as a colorless liquid.

[0531] Step 4: Synthesis of 8,8'-((4-(((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azinediyl)dioctanoic acid di(heptadecan-9-yl) ester (PVXL-202)

[0532] At room temperature, NH3 (3 mL, 7 M, in MeOH) was added to a stirred solution of 8,8'-((4-(((2R,3R,4R,5R)-3,4-diacetoxy-5-(acetoxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azinediyl)dioctanoic acid di(heptadecano-9-yl) ester (7) (200 mg, 0.18 mmol) in MeOH (0.5 mL), and the reaction mixture was stirred for 24 h. After 24 h, the reaction mixture was quenched with ice-cold water (20 mL), stirred for 10 min, and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (20 mL), dehydrated on Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude product. This crude product was purified by combiflash chromatography using 50-60% EtOAc in heptane as the eluent to obtain 8,8'-((4-(((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)butyl)azanediyl)dioctanoic acid di(heptadecan-9-yl) ester (PVXL-202) (30 mg, 15%, two steps) as a colorless colloidal substance.

[0533] [ 1 H NMR (401 MHz, MeOD) δ 0.86 - 0.93 (m, 12H), 1.26 - 1.37 (m, 61H), 1.53 (dd, J = 13.1, 6.9 Hz, 15H), 1.58 - 1.67 (m, 5H), 2.30 (t, J = 7.2 Hz,4H), 2.43 - 2.63 (m, 6H), 3.37 -3.43 (m, 1H), 3.51 - 3.58 (m, 1H), 3.70 (d, J= 3.4 Hz, 1H), 3.72 - 3.77 (m, 1H), 3.85 - 3.88 (m, 1H), 3.89 - 3.95 (m, 1H), 4.03 (dd, J = 6.9, 4.8 Hz, 1H), 4.84 - 4.85 (m, 1H), 4.87 - 4.90 (m, 2H).]

[0534] Example 2: Preparation of lipid nanoparticle composition

[0535] The cationic lipid (PVXL-202) was synthesized according to the method described in Example 1. The phospholipids used in the LNP composition [1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC) or 2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE)] were purchased from BOC Sciences, TCI America, or Sinopec. Cholesterol was purchased from BOC Sciences or Merck. PEG-lipids [1,2-dimyristoyl-racemic-glycerol-3-methoxy polyethylene glycol 2000 (mPEG2000-DMG) or α-(3'-{[1,2-di(myristyloxy)propoxy]carbonylamino}propyl)-ω-methoxypolyoxyethylene (mPEG2000C-DMG)] were purchased from Sinopec or BOC Sciences, respectively.

[0536] Luciferase mRNA is synthesized using conventional in vitro transcription (IVT) techniques known to those skilled in the art.

[0537] Different lipid nanoparticle compositions with different molar percentages of lipids mentioned in Table 2 were prepared.

[0538] Table 2: Lipid Nanoparticle Compositions

[0539] F-ID: Formulation ID

[0540] CL: cationic lipids

[0541] PL: Phospholipids

[0542] Chol: cholesterol

[0543] PEG-L: Polyethylene Glycol-Lipid

[0544] N:P: ratio of cationic lipids to nucleic acids

[0545] Nucleic acid (luciferase mRNA) was dissolved in an aqueous phase (25 mM sodium acetate buffer, pH 5.0), and lipid components (cationic lipids, phospholipids, cholesterol, and PEG-lipids) were dissolved in an organic phase (IPEC grade 99.5% (v / v) ethanol). The aqueous (continuous) and organic (dispersed) phases were mixed in a microfluidic device (AXF Mini, Micropore Technologies) using a dual-syringe pump (Microlab 600 Advanced Dual-Syringe Diluter, Hamilton Company, catalog number ML625-DIL-BZ). The total flow rate was maintained at 100 mL / min or 300 mL / min, and the flow rate ratio (FRR) of the aqueous to organic phase was 3:1. Lipid nanoparticles were buffer-exchanged with phosphate-buffered saline (PBS) at pH 7.5 or Tris-acetate-sucrose using an Amicon® Ultra 15 (catalog number UFC910096) or a 100 kDa TFF membrane pack (catalog number VF05H4, Sartorius), followed by aseptic filtration using a 0.22 μm PES filter (catalog number SF-13-100NO, HiMediaLaboratories).

[0546] Example 3: Characterization of LNP Composition

[0547] Particle size, zeta potential, and polydispersity index (PDI)

[0548] The particle size, zeta potential, and polydispersity index (PDI) of different lipid nanoparticle compositions were determined using a particle analyzer (LiteSizer 500, catalog number 155761, Anton Paar) by diluting the compositions in nuclease-free water.

[0549] Encapsulation efficiency

[0550] The encapsulation efficiency of the lipid nanoparticle compositions was quantified using the Quant iT RiboGreen RNA Assay Kit (catalog number R11490, ThermoFisher Scientific) by measuring free mRNA and total mRNA. Briefly, the LNP compositions were diluted with 1X TE buffer and transferred to 96-well plates in duplicate. Another set of LNP compositions was diluted with 1X TE buffer containing 1% Triton to lyse the LNPs and added to adjacent wells on the same plate in duplicate. The plates were incubated at 37°C for 10 min. RNA standards from the assay kit were serially diluted in 1X TE buffer and 1X TE buffer containing 1% Triton, and added in duplicate to the same plate. To estimate background from the buffers, 1X TE buffer and 1X TE buffer containing 1% Triton were added in duplicate to the same plate as a blank for measurement. Ribogreen dye was thawed in the dark at room temperature, diluted with 1X TE buffer, and added to all wells. The plate was read using a microplate reader (Spark multimode microplate reader from TECAN, catalog number 30086376), and fluorescence was measured using an excitation wavelength of 485 nm and an emission wavelength of 528 nm. Two standard curves were plotted against standards in 1X TE buffer and 1X TE buffer containing 1% Triton, and the free and total mRNA were calculated by subtracting the blank (if any) from the corresponding standard curves. Encapsulation efficiency was determined as follows:

[0551] The characterization results of the LNP compositions are summarized in Table 3.

[0552] Table 3: Characterization of LNP compositions

[0553] F-ID: Formulation ID

[0554] CL: cationic lipids

[0555] PL: Phospholipids

[0556] Chol: cholesterol

[0557] PEG-L: Polyethylene Glycol-Lipid

[0558] N:P: ratio of cationic lipids to nucleic acids

[0559] EE: Encapsulation efficiency

[0560] ζ: ζ potential

[0561] PDI: Multidispersion Index

[0562] Example 4: Determination of the translational efficacy of lipid nanoparticle compositions by luciferase assay

[0563] The translational efficacy of the lipid nanoparticle composition was estimated by measuring luciferase expression using a luciferase assay. HEK293T cells (Catalogue No. CRL-1573) from ATCC were cultured in DMEM high-glucose medium (Catalogue No. 11995-065, ThermoFisher Scientific) [supplemented with L-glutamine, sodium pyruvate, 10% FBS (Catalogue No. 10270-106, ThermoFisher Scientific), and 1% penicillin-streptomycin (Catalogue No. 15140122, ThermoFisher Scientific)] at 37°C and 5% CO2 under humid conditions. 24 hours before transfection, cells were sputtered at 0.5 x 10⁶ cells per well. 5 Cells were seeded at a density of 100 μg / well in 24-well plates. 250 ng of lipid nanoparticles encapsulating luciferase mRNA (luciferase LNP-mRNA) were added to each well. The plates were incubated at 37°C and 5% CO2 for 24 hours. After incubation, the culture medium was removed, and the cells were lysed with 125 μl of reporter lysis buffer (catalog number E4030, luciferase assay system with reporter lysis buffer, Promega). The lysate was then incubated at room temperature with stirring at 600 rpm on a heat mixer C (catalog number EP5382000023, Eppendorf), and the supernatant was collected. 20 μl of supernatant was added to each well of a black flat-bottomed 96-well plate, and 100 μl of luciferin substrate (catalog number E4030, luciferase assay system with reporter lysis buffer, Promega) was added to each well. Immediately after substrate addition, luminescence was measured using a microplate reader (catalog number 30086376, Spark multimode microplate reader, TECAN). Results are shown in... Figure 1 middle.

[0564] By incorporating references

[0565] Every patent, published patent application or provisional application, and non-patent reference cited in this article is incorporated herein in its entirety by reference.

[0566] equivalent

[0567] Those skilled in the art will recognize or be able to determine numerous equivalents of specific embodiments of the invention described herein using only conventional experiments. These equivalents are intended to be covered by the claims.

Claims

1. A cationic lipid represented by formula (I) or an isomer or salt thereof: Formula (I), in: R1 and R2 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L7-R5 and -NR6R7; R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L6, and L7 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide and C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N, provided that when A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or S, one of R1 or R2 does not exist; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

2. A cationic lipid represented by formula (II) or an isomer or salt thereof: Equation (II), in: R3 and R4 are independently selected from branched or non-branched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range 0 to 26 independently; (R 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 heteroaryl, -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4; R5, R6, and R7 are independently selected from H, -OH, and C. 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Each of L1, L2, L3, L4, L5, L7, and L8 either does not exist or is independently selected from C. 1-10 Alkylene, C 2-10 imide or C 2-10 Ethyne group; X1 and X2 are independently selected from -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- and -OP(O)(O-)O-; A is H, bond, saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatics; Z is -CH2-, O, N, or S; A1 is -CH2-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O-, S or N; and Each of the alkyl, alkenyl, ynylene, alkylene, alkenylene, ynylene, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl groups may be independently and optionally substituted by one or more substituents.

3. The cationic lipid according to claim 1, wherein R1 and R2 are each independently H or -OH.

4. The cationic lipid according to claim 1, wherein R1 and R2 are each independently C 1-10 alkyl.

5. The cationic lipid according to claim 1, wherein R1 and R2 are each independently C 2-10 Alkenyl group.

6. The cationic lipid according to claim 1, wherein R1 and R2 are each independently C 2-10 Alkyne group.

7. The cationic lipid according to claim 1, wherein R1 and R2 are each independently saturated or unsaturated C. 3-10 Cycloalkyl.

8. The cationic lipid according to claim 1, wherein R1 and R2 are each independently a saturated or unsaturated C1 or C2 containing 1-4 heteroatoms. 3-10 Heterocyclic alkyl groups.

9. The cationic lipid according to claim 1, wherein R1 and R2 are each independently H or -O-L7-R5.

10. The cationic lipid according to claim 1, wherein R1 and R2 are each independently H or -NR6R7.

11. The cationic lipid according to claim 2, wherein Z is -CH2-, O, N or S.

12. The cationic lipid according to claim 2 or claim 11, wherein (R) 10 ) q Selected from H, -OH, -CH2OH, C 1-10 Alkyl, C 2-10 alkenyl, C 2-10 Alkyne group, saturated or unsaturated C 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, C containing 1-4 heteroatoms 5-10 The aryl groups are -O-L8-R5 and -NR6R7, where q is an integer in the range of 0 to 4.

13. The cationic lipid according to claim 12, wherein (R) 10 ) q H is a variable where q is an integer in the range of 0 to 4.

14. The cationic lipid according to claim 12, wherein (R) 10 ) q Selected from -OH and -CH2OH, where q is an integer in the range of 0 to 4.

15. The cationic lipid according to claim 12, wherein (R) 10 ) q It is C 1-10 Alkyl group, where q is an integer in the range of 0 to 4.

16. The cationic lipid according to claim 12, wherein (R) 10 ) q It is C 2-10 Alkenyl, where q is an integer in the range of 0 to 4.

17. The cationic lipid according to claim 12, wherein (R) 10 ) q It is C 2-10 Alkyne group, where q is an integer in the range of 0 to 4.

18. The cationic lipid according to claim 12, wherein (R) 10 ) q Is it saturated or unsaturated C? 3-10 Cycloalkyl, where q is an integer in the range of 0 to 4.

19. The cationic lipid according to claim 12, wherein (R) 10 ) q It is a saturated or unsaturated carbon containing 1-4 heteroatoms. 3-10 Heterocyclic alkyl groups, where q is an integer in the range of 0 to 4.

20. The cationic lipid according to claim 12, wherein (R) 10 ) q It is -O-L8-R5, where q is an integer in the range of 0 to 4.

21. The cationic lipid according to claim 12, wherein (R) 10 ) q It is -NR6R7, where q is an integer in the range of 0 to 4.

22. The cationic lipid according to any one of claims 12-21, wherein q is an integer in the range of 0 to 3, 0 to 2, or 0 to 1.

23. The cationic lipid according to any one of claims 1-2 or 9, wherein L7 is either absent or is C 1-10 Alkylene, C 2-10 imide or C 2-10 Alynyl group.

24. The cationic lipid of claim 23, wherein L7 is absent.

25. The cationic lipid of claim 20, wherein L8 is either absent or is C 1-10 Alkylene, C 2-10 imide or C 2-10 Alynyl group.

26. The cationic lipid of claim 25, wherein L8 is absent.

27. The cationic lipid according to claim 9 or claim 20, wherein R5 is H, -OH, C 1-10 Alkyl, saturated or unsaturated C 3-10 Cycloalkyl groups, saturated or unsaturated C atoms containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

28. The cationic lipid of claim 27, wherein R5 is a C containing 1-4 heteroatoms. 3-6 Heterocyclic alkyl groups.

29. The cationic lipid according to claim 27, wherein R5 is a C containing 1-4 heteroatoms. 5-9 Mixed aromatic compounds.

30. The cationic lipid according to claim 10 or claim 21, wherein R6 and R7 are independently selected from H, -OH, C. 1-10 Alkyl, saturated or unsaturated C 3-10 Cycloalkyl groups, saturated or unsaturated C atoms containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups and C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

31. The cationic lipid of claim 30, wherein R6 and R7 are independently selected from H, -OH, C. 1-6 Alkyl groups and saturated or unsaturated C groups containing 1-4 heteroatoms 3-8 Heterocyclic alkyl groups.

32. The cationic lipid according to any one of the preceding claims, wherein R3 and R4 are independently selected from branched or unbranched C. 1-26 Alkyl, C 2-26 alkenyl, C 2-26 Alkyne group, -(CH2) m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

33. The cationic lipid of claim 32, wherein R3 and R4 are independently selected from C 1-20 Alkyl, C 2-20 alkenyl and C 2-20 Alkyne group.

34. The cationic lipid of claim 32, wherein R3 and R4 are independently selected from -(CH2). m -A-(CH2) n -(CH3) y and -CH((CH2) m -A-(CH2) n -(CH3) y )2, where each of m, n and y is an integer in the range of 0 to 26.

35. The cationic lipid according to claim 32 or claim 34, wherein m, n and y are each independently an integer in the range of 0 to 20, 0 to 16, 0 to 12, 0 to 10 or 0 to 8.

36. The cationic lipid according to any one of the preceding claims, wherein L1 and L2 are independently selected from C 1-10 Alkylene, C 1-8 Alkylene, C 1-6 Alkylene, C 1-4 Alkylene, C 1-3 Alkylene and C 1-2 Alkylene.

37. The cationic lipid according to any one of the preceding claims, wherein L1 and L2 are independently selected from C 2-10 imidene group, C 2-8 imidene group, C 2-6 imide and C 2-4 Alkenyl group.

38. The cationic lipid according to any one of the preceding claims, wherein L3 and L4 are independently selected from C 1-10 Alkylene, C 1-8 Alkylene, C 1-6 Alkylene, C 1-4 Alkylene, C 1-3 Alkylene and C 1-2 Alkylene.

39. The cationic lipid according to any one of the preceding claims, wherein L3 and L4 are independently selected from C 2-10 imidene group, C 2-8 imidene group, C 2-6 imide and C 2-4 Alkenyl group.

40. The cationic lipid according to any one of the preceding claims, wherein L5 is either absent or independently selected from C 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

41. The cationic lipid according to any one of the preceding claims, wherein L6 is either absent or independently selected from C 1-10 Alkylene, C 2-10 imide and C 2-10 Alynyl group.

42. The cationic lipid according to any one of claims 40-41, wherein L5 and L6 are absent.

43. The cationic lipid according to any one of the preceding claims, wherein X1 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

44. The cationic lipid according to claim 43, wherein X1 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

45. The cationic lipid according to any one of the preceding claims, wherein X2 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, -C(S)O-, -OC(S)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

46. ​​The cationic lipid according to claim 45, wherein X2 is -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, -OP(O)(OH)O- or -OP(O)(O-)O-.

47. The cationic lipid according to any one of the preceding claims, wherein A is H, a bond, or a saturated or unsaturated C. 3-10 cycloalkyl, C 6-10 Aryl groups, saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups or C groups containing 1-4 heteroatoms 5-10 Mixed aromatic compounds.

48. The cationic lipid of claim 47, wherein A is a saturated or unsaturated C. 3-10 Cycloalkyl groups or saturated or unsaturated C groups containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups.

49. The cationic lipid according to any one of the preceding claims, wherein A1 is -CH2- or N.

50. The cationic lipid according to any one of the preceding claims, wherein the heteroatom is selected from O, N, S or P.

51. The cationic lipid of claim 50, wherein the heteroatom is selected from O, N or S.

52. The cationic lipid according to any one of the preceding claims, wherein each alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group is independently optionally substituted by one or more substituents.

53. The cationic lipid according to claim 52, wherein the substituent is selected from H, -OH, Cl, Br, I, O, S, N, P, and optionally substituted C. 1-6 Alkoxy, optional substituted C 1-6 Alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 Alkyne group, optionally substituted saturated or unsaturated C 3-10 cycloalkyl, optionally substituted C 6-10 Aryl, optionally substituted saturated or unsaturated C-type compounds containing 1-4 heteroatoms 3-10 Heterocyclic alkyl groups, optionally substituted C groups containing 1-4 heteroatoms 5-10 heteroaryl groups or combinations thereof.

54. A lipid nanoparticle composition comprising a cationic lipid according to any one of claims 1-53, and optionally additionally comprising phospholipids, sterols, PEG-lipids, or nucleic acids.

55. A lipid nanoparticle composition comprising a cationic lipid, phospholipid, sterol, PEG-lipid, and nucleic acid as described in any one of claims 1-53.

56. The lipid nanoparticle composition according to claims 54-55, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%.

57. The lipid nanoparticle composition according to claims 54-55, wherein the phospholipid is present in an amount of 2 mol% to 65 mol%.

58. The lipid nanoparticle composition according to claims 54-55, wherein the sterol is present in an amount of 20 mol% to 65 mol%.

59. The lipid nanoparticle composition according to claims 54-55, wherein the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

60. The lipid nanoparticle composition according to any one of claims 54-59, wherein the cationic lipid is present in an amount of 10 mol% to 70 mol%, the phospholipid is present in an amount of 2 mol% to 65 mol%, the sterol is present in an amount of 20 mol% to 65 mol%, and the PEG-lipid is present in an amount of 0.2 mol% to 2.0 mol%.

61. The lipid nanoparticle composition according to any one of claims 54-60, further comprising an ionizable polymer.

62. The lipid nanoparticle composition according to claim 61, wherein the ionizable polymer is present in an amount of 1 mol% to 25 mol%.

63. The lipid nanoparticle composition according to any one of claims 54-62, wherein the nucleic acid is DNA, RNA, or a combination thereof.

64. The lipid nanoparticle composition according to claim 63, wherein the RNA is mRNA, long non-coding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), PIWI-interacting RNA (piRNA), or a combination thereof.

65. The lipid nanoparticle composition according to claim 64, wherein the RNA is mRNA.

66. The lipid nanoparticle composition of claim 65, wherein the mRNA encodes one or more proteins, one or more antibodies, or a combination thereof.

67. The lipid nanoparticle composition according to claim 65, wherein the mRNA encodes an antigen derived from a prokaryote or eukaryote, a single-celled organism, a multicellular organism, a virus, bacteria, mycoplasma, a protozoan, an animal, or a human.

68. A method of treating or preventing a disease, the method comprising administering to a subject in need the lipid nanoparticle composition according to any one of claims 54-67.

69. Use of the lipid nanoparticle composition according to any one of claims 54-67 in the preparation of a medicament for treating or preventing disease in a subject.

70. A method for delivering nucleic acids, the method comprising applying a lipid nanoparticle composition comprising a cationic lipid, phospholipid, sterol, PEG-lipid, and nucleic acid as described in any one of claims 1-53.

Citation Information

Patent Citations

  • Large scale synthesis of messenger RNA

    WO2018157153A1

  • Compression release brake arrangement, method of controlling a compression release brake arrangement, and related devices

    WO2019151927A1

  • Fed-batch in vitro transcription process

    WO2020185811A1

  • Large scale synthesis of messenger RNA

    WO2022082001A1